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ABSTRACT 
Jarod Waybright: A Chemical Biology Approach to Phosphoinositide Metabolic Analysis 
(Under the direction of Qisheng Zhang) 
 
 Lipids serve a diverse array of functions including maintaining cellular structure and 
compartmentalization, regulating post-translational modifications of proteins, and as members of 
complex signaling networks. Despite their importance there is minimal understanding of how 
bioactive lipids and lipid pathways systematically regulate biological processes. 
Phosphoinositides (PIPs) are a diverse class of lipid signaling molecule implicated in nearly all 
facets of cell signaling including migration, proliferation, and apoptosis. Mutations in numerous 
PIP modifying enzymes occur frequently in human disease, especially cancers, though the 
effects of these mutations on the global metabolic system have been poorly defined. Likewise, 
heterogeneous protein expression and undefined feedback loops further complicate obtaining a 
global view of metabolism and understanding the PIP metabolic pathway’s role in disease. 
Current approaches have been unsuccessful in obtaining a systems-wide analysis due to various 
technical challenges including low sensitivity, use of indirect measurements of activity, and a lack 
of validated reporters and delivery methods.  
 We have developed a new approach to systematic PIP analysis including synthesis and 
validation of fluorescent reporters, novel PIP delivery methods, and applying these methods to 
analyze PIP metabolism in breast cancer cell lines. We have shown that hydrophobicity is a key 
determinant in the ability of fluorescent reporters to serve as substrates for phosphoinositides 
modifying enzymes, which proceed via interfacial catalysis, through chemical synthesis of 
fluorescent phosphoinositides with varied hydrophobicity in the diacylglycerol (DAG) side chain 
and examined their propensity to serve as substrates towards various enzymes. We used these 
	 iv	
findings to develop a suite of fluorescent reporters that could subsequently be used as standards 
and reporters in future experimentation.  
 To achieve our goal of systematically analyzing cellular metabolism, we examined a 
variety of delivery methods for fluorescent PIPs as previously reported techniques have failed to 
achieve a level of delivery sufficient for metabolic analysis. We further developed a fluorescent 
model phospholipid that allowed us to explore novel delivery techniques including intramolecular 
charge masking and photocaging methods while simultaneously exploring previously published 
methods including liposomes and charge altering releasable transporters (CARTs) for the 
delivery of PIPs. 
  A PIP2:CART complex was demonstrated to efficiently deliver fluorescent PIP2 to cells, 
which were then analyzed for their metabolite distribution. This method was effective in achieving 
conversion of the fluorescent reporter to a variety of PIP substrates as judged by comparison 
with synthetic standards. We further applied this system to preliminary studies on breast cancer 
cell lines possessing unique mutations in PIP modifying enzymes. We have thus far been 
successful in demonstrating a platform using fluorescent PIP reporters, novel delivery techniques 
that lead to a variety of metabolites than can be analyzed by capillary electrophoresis (CE) or 
thin layer chromatography (TLC). This system could be a powerful tool in future studies of PIP 
metabolism in human disease with potential diagnostic applications.  
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CHAPTER 1. INTRODUCTION AND IMPORTANCE OF SYSTEMATIC ANALYSIS OF 
BIOACTIVE LIPIDS 
 
1.1		Importance	of	Bioactive	Lipids	
Lipids are responsible for diverse and vital cellular processes with variations in 
lipid head groups and aliphatic chains allowing for the existence of >1,000 different lipid 
species [1, 2]. While largely recognized as being important structural components of the 
cell allowing for compartmentalization of cellular tasks, lipids also serve as critical 
regulators of a wide array of biological outcomes. Lipids can serve as an energy 
sources in times of glucose depletion. Fatty acids can be hydrolyzed from phospholipids 
that enter a stepwise pathway leading to the generation of acetyl CoA, that provides 
needed carbon atoms to the Kreb’s cycle where they can be oxidized for energy 
production [3]. Lipids can also serve as post-translational modifications of proteins such 
as the addition of myristoyl group to the N-terminal of the protein leading to membrane 
association, subcellular localization, and protein-protein interactions [4].  
Lipid metabolites are also important signaling metabolites that control a wide 
array of cellular processes including cell proliferation, migration, and apoptosis [5]. 
Signaling lipids, such as sphingolipids and phosphoinositides (PIPs), are large networks 
of metabolites and enzymes that respond uniquely to various extracellular and 
intracellular stimuli that lead to specific cellular functions [3, 5]. For instance 
phosphoinositides metabolic enzymes respond to both extracellular stimulation of 
receptor tyrosine kinases such epidermal growth factor receptor (EGFR) and platelet 
	2	
derived growth factor receptor (PDGFR) that lead to downstream signaling cascades 
generally promoting cell survival and growth [6-8]. Likewise, a separate subset of PIP 
modifying enzymes can also be stimulated by Wnt leading to activation of a separate 
signaling cascade Wnt [9, 10]. Interestingly, PIP pathways also respond to intracellular 
production of lipid metabolites possibly as a feedback mechanism to control the ratios of 
the various metabolites which will be highlighted in the future sections and summarized 
in Table 1.1 [11]. 
1.2  Importance of Systematic Analysis of Lipid metabolites 
Because of the broad role of lipid signaling molecules, various enzymes within 
different pathways control the levels of various lipid metabolites very tightly to maintain 
cellular homeostasis. Imbalances of these metabolites contribute to a wide variety of 
human diseases including neuro-degeneration and cancers [5]. For example, mutations 
in the lipid modifying enzyme phosphoinositides 3-kinase (PI3K) leads to an increase 
production of signaling metabolite phosphoinositide 3,4,5-trisphosphate (PIP3). This 
increased production of PIP3 is important in cancer onset and progression [12]. 
Likewise, imbalances resulting from the increased production of another lipid metabolite 
phosphoinsitide 4-phosphate (PI(4)P) by aberrant phosphoinositide 4-kinase (PI4K) has 
implications in mental health diseases such as bi-polar disorder highlighting the 
complexity and reach of lipid metabolism in disease [13]. However, due to the 
complexity of the lipid signaling pathways, areas of aberrant activity have been studied 
in isolation focusing on a single node of activity separate from the rest of the metabolic 
network [14-16]. This has most commonly been done using methods such as dominant 
negative enzymes, siRNA interference, as well as through the development of small 
molecule chemical probes for biological analysis [15-19]. However, this method of 
	3	
analysis has raised many questions about the contributions of the total metabolic 
pathway versus that of just a single metabolite because of the interconnected lipid 
pathways [20]. Indeed, there are crosstalk and feedback mechanisms among various 
lipid metabolites within a single pathway as well as interactions between various classes 
of bioactive lipids [21, 22].  For instance, the sphingolipid and phosphoinositides 
metabolic pathways have shown to interact through stimulation of diacylglycerol kinase 
(DAGK) activity. Cells treated with increasing concentrations of sphingosine lead to an 
increase in phosphatidic acid (PA) production suggesting the pathways are intertwined 
[21]. Therefore understanding the systems contributions of the various classes of 
bioactive lipids would be invaluable to understanding their importance in biological 
processes and diseases [20]. Despite the importance of the lipid signaling metabolic 
networks, little is known about the interplay between metabolites in cellular processes 
due to the difficulty in studying multiple metabolic events systematically within the cell 
[20]. 
 
Substrate	 Interacting	Enzyme	 Result	
DAG	 DAGK	 	Stimulated	
DAG	 PKC	 	Stimulated	
Sphingosine	 DAGK	 	Stimulated	
PI(3,4,5)P3	(Increase)	 DAGK	 	Stimulated	
PI(3,4,5)P3	(Depleted)	 DAGK	 	Increased	Expression	
PI(4,5)P2	 PLC	 	Stimulated	
PI(4)P	 PI4P5K	 Stimulated	
Table	1.1	Summary	of	Interactions	Within	Lipid	Signaling	Networks21,	22,	
23,	59,	60,	61		
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1.3 Importance of Phosphoinositides 
1.3.1 Background on Phosphoinositides  
Phosphoinositides (PIPs) are a vital class of signaling lipids that also play critical 
roles in a variety of cellular processes and human diseases, especially cancers [5, 12, 
13, 16, 23-28]. PIPs constitute approximately 1% of the phospholipids in the cell 
membranes and as one of the most versatile family of signaling molecules, PIPs play 
important roles in numerous facets of cell signaling, cell motility, vesicle transport and 
development [19, 29-33]. All PIPs are derived from phosphatidylnositol (PtdIns), which 
can be reversibly phosphorylated on the hydroxyl groups at the C3, C4, and C5 
positions to generate seven endogenous PIPs as illustrated in Figure 1.1A [34, 35]. 
PIPs contain a diacylglycerol (DAG) side chain most commonly containing stearic and 
the polyunsaturated arachiadonic acid that anchors them to various subcellular 
membranes. Because of wide variety of roles that PIPs play in cellular metabolism, 
there is stringent temporal and spatial control over metabolite generation. 
Consequently, abnormal levels of PIPs have been associated with development of a 
wide range of diseases including cancers and neurodegenerative disorders [36-38] 
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1.3.2 Cellular Distribution of PIPs 
PIPs are found distributed on specific membranes and the abundance of each 
lipid is tightly controlled giving great spatial and temporal control of the pathway [2].  As 
shown in Figure 1.1B, PtdIns is modified to generate a pool of 7 PIPs through 
reversible phosphorylation of the C3, C4, and C5 hydroxyl groups that are distributed 
A.	
		
B.	
	
Figure 1.1 Structure and Metabolic Pathway of 
Phosphoinositides: A. General Structure of Phosphonisositides 
(PIPs). Phosphoinositides are composed of a myo-inositol head 
group that can be selectively phosphorylated at the 3,4, and 5 
position. It is linked to a DAG chain via a phosphodiester bond 
with the sn-1 position. The DAG chain most commonly contains 
arachidonic acid and stearic acid at the sn-2 and sn-3 positions, 
respectively. B. The PIP Metabolic Network. The PIP metabolic 
network is a collective of kinases and phosphatases responsible 
for the generation of 7 distinct phosphorylated PIPs.  	
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throughout various cell membranes [34, 35]. These lipid metabolites are distributed 
throughout various membranes as summarized in Table 1.2. The most abundant of the 
PIPs in cells are phosphoinositides 4,5-bisphosphate (PI(4,5)P2; PIP2) and 
phosphoinositide 4-phosphate (PI(4)P) which are important precursors to generate 
second messenger PI(3,4,5)P3. Because of the potent signaling functions of PIP3 it is 
generally found at only ~2—5% of the levels of PIP2 at basal conditions [20, 34, 39]. 
PIP2 Other low abundance PIPs, such as PI(3)P and PI(3,5)P2 are found primarily in 
various endosomes and lysosomes while PI(5)P has been shown to be both a nuclear 
and cytosolic signaling molecule underscoring the vast diversity amongst distribution 
and function of PIPs [33, 39]. 
 
1.3.3 Cellular Functions of Phosphoinositides 
The various PIPs are generated from a collective of kinases and phosphatases 
that make up the PIP metabolic network. PIP modifying enzymes can be stimulated 
through a variety of receptors including G-Protein coupled receptors (GPCRs) and 
receptor tyrosine kinases (RTKs) by corresponding ligands allowing for temporal control 
	
Metabolite Location 
PI(4)P Golgi/Vesicles 
PI(4,5)P2 
Plasma 
Membrane 
PI(3,4,5)P3 
Plasma 
Membrane 
PI(3,4)P2 Vesicles 
PI(3)P 
Early 
Endosome 
Table 1.2 Cellular Distribution of PIPs38: 
Metabolites of the PIP metabolic pathway 
are distributed amongst specific organelles. 	
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over the generation of metabolites [33, 35]. PIPs have a wide range of downstream 
targets and cellular functions through interacting with targets at or recruited to the 
membrane [34, 35]. Effector proteins are recruited to cellular membranes via 
stereospecific binding to the phosphorylated inositol head groups enabling spatial 
organization and control [39]. One such example is the pleckstrin homology (PH) 
domain, the most abundant lipid-binding domain, which binds to numerous 
phosphorylated metabolites as seen in Figure 1.2 [13, 40]. Effector proteins, such as 
Akt (PKB), contain PH domains that localize the protein to the membrane allowing for 
activation and downstream signaling effects. This further highlights the importance of 
stringent control over production of secondary signaling metabolites [33, 34]. 
 
1.4 The PI3K Metabolic Pathway 
1.4.1 Background  
 
The PI3K pathway is a localized metabolic pathway of 4 enzymes and 4 
metabolites within the larger PIP metabolic network  and is illustrated in Figure 1.3 [41, 
42]. The central enzyme phosphoinositide 3-kinase (PI3K) is responsible for generation 
	
Figure 1.2 PIP Binding Effector Protein Domains: Various 
protein domains and their PIP target. Effector proteins 
recognize phosphorylation patterns of PIPs and are recruited 
to cellular membranes for activation.  
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of potent second messenger PI(3,4,5)P3 (PIP3) from the most abundant PIP metabolite 
PI(4,5)P2.  In addition to PI3K, the pathway contains 3 phosphatases responsible for 
diminishing the pool of PIP3: phosphatase and tensin homolog (PTEN), Phosphoinostol-
3,4,5-trisphosphate 5-phosphatase 1 (SHIP1), as well as the inositol polyphosphate 4-
phosphatase type II (INPP4B) [14, 25, 38]. While the resulting reaction does not 
generate a PIP, phospholipase C (PLC) is also an important enzyme that is relevant to 
the PI3K pathway as PLC and PI3K share PI(4,5)P2 as a substrate and respond to 
many of the same stimuli [33]. Other signaling metabolites DAG and inositol 1,4,5-
triphosphate (IP3) that are generated by PLC also serve as important regulators of the 
PIP metabolic pathway and cellular functions as second messengers [5]. 
 
1.4.2 The Importance of PI3K in Human Disease 
Genes encoding for the PIP modifying enzyme PI3K are found frequently 
mutated in a variety of cancers summarized in Table 1.3 [12, 13, 23, 43-45]. Class 1A 
	
	
Figure 1.3The PI3K Metabolic Pathway: The enzymes and metabolites 
that make up the PI3K metabolic pathway with PI(4,5)P2 supplied from 
PtdIns via PI(4)P. 
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PI3Ks are heterodimers composed of a p110 catalytic subunit responsible for 
generation of PIP3, and a p85 regulatory subunit responsible for auto-inhibition of the 
enzyme [46, 47]. Mutations in the helical and kinase domains of the protein result in 
increased enzymatic activity through both increased lipid binding and relief of p85 auto-
inhibition resulting in a increase in PIP3 production [23, 46, 47]. Increases in PIP3 levels 
drive tumorigenesis due to an increased activation of the PH domain containing effector 
protein Akt (PKB), which is activated following binding to PIP3  [25, 38, 48]. The increase 
in Akt activation results in misregulated downstream signaling of effector proteins 
including inhibition of transcription factor forkhead box 01 (FOX01) and increased 
activity of anti-apoptotic proteins such as nuclear factor kB (NFkB) and mammalian 
target of rapamaycin (mTOR), all important in tumorigenesis [14, 49, 50]. Interestingly the 
conversion of PI(3,4,5)P3 to PI(3,4)P2 by the SHIP family of phosphatases does not 
reduce Akt activation and it has been shown that both metabolites are capable of PH 
domain binding and Akt activation[40]. Therefore, both PTEN and INPP4B are 
responsible for direct termination of PI3K/Akt signaling through depletion of both 
PI(3,4,5)P3 and PI(3,4)P2 respectively, suggesting tumor suppressor potential for both of 
these enzymes. Indeed, knockdowns of both PTEN and INPP4B results in increased 
Akt activation leading to increased anchorage independent growth and cell motility. 
Likewise, deletion of PTEN or INPP4B in mice leads to an increase in tumor size in 
various xenograft models, further validating the tumor suppressor function of these 
enzymes [24, 28, 40, 45, 51, 52]. Not surprisingly, loss of PTEN expression or activity is 
common in human cancers and is the second most mutated tumor suppressor gene in 
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human cancer behind p53[52]. Collectively, these findings have made the PI3K pathway 
an attractive target for pharmaceutical development [14, 16, 38, 49, 50, 53]. 
 
Highlighting this need of expanded analytical techniques, a study6 of MCF10A 
cell populations using flow cytometry revealed heterogeneity in PI3K activity that was 
previously unknown due to measurement of population averages. In this study, a 
bimodal distribution of Akt activity was observed following EGF stimulation that 
correlates with PI3K protein production. Interestingly, the same distribution of PI3K was 
observed on a single cell level for both wild type and mutant PI3KH1047R suggesting that 
only a subset of cells classified as having a high levels of PI3K can activate Akt [7]. 
Because cell-to-cell variability has been demonstrated in multiple systems can lead to 
unique cellular fates and understanding how this is maintained and regulated could be a 
powerful tool in basic biology and pharmaceutical targeting of PI3K [54, 55]. For 
instance, targeting a population of cells are expressing low quantities of mutant PI3K 
with low Akt activation may be unsuitable for achieving a positive therapeutic effect [16]. 
Therefore, a simple and effective diagnostic tool to better understand this heterogeneity 
and PI3K activity in a patient could be effective in better determining a method and time 
of treatment.  
Disease	 Frequency	(%)	
Head	and	Neck	Cancer	 42	
Breast	Cancer	 25	
Lung	Cancer	(Squamous	
Cell)	 53	
Colorectal	Cancer	 37	
Lung	Cancer	(Small	Cell)	 27	
Table	 1.3	 Summary	 of	 Frequency	 of	PIK3CA	
Alterations	in	Human	Cancer6,10,12,	30		
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1.4.3 Pharmaceutical Targeting of PI3K Pathway  
 Attempts at therapeutic intervention against the PI3K pathway have been made 
by targeting PI3K directly as well as downstream effectors of the pathway. Indeed, the 
PI3K-d selective inhibitor, idelalisib, has been approved by the FDA to treat chronic 
lympocytic leukemia in combination with rituximab though only as a third line treatment 
following multiple treatment failures [56]. Likewise, the drug was pulled from multiple 
clinical trials in 2016 due to lack of efficacy.  Pan PI3K inhibitors represent the largest 
class of agents used to regulate aberrant PI3K activity [14, 16, 49, 57, 58]. 
Unfortunately, such a strategy has proven to be difficult in achieving clinical success 
and raises questions regarding the possible off-target effects of inhibiting all isoforms of 
PI3K versus the oncogenic PI3Kα mutant [49]. Akt inhibition is the second most 
common target of pharmacological agent for PI3K aberrant cancers, but this too has 
seen little positive clinical outcomes [14, 16, 34, 49]. Such failures in the clinic have 
raised numerous interesting and important biological questions that are essential in 
understanding the complex nature of the PI3K signaling network, as well as the PI 
metabolic pathway as a whole. One such goal is understanding the roles of various 
metabolites within the pathway and possible feedback loops across various cancer 
types [14, 16, 49, 57]. Likewise, it places an emphasis on achieving a systems 
understanding of PIP biology within a tumor microenvironment, especially with the 
previously described cell-to-cell variability of PI3K and Akt activation [3, 7]. It is 
hypothesized that inhibition of PI3K or Akt is overcome by compensatory lipid signaling 
pathways over time allowing for the cell to evade deleterious effects of inhibition.  
 Supporting this hypothesis of compensatory pathways, products of the PI3K 
pathway have been shown to alter levels of other PI modifying enzymes including 
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DAGK, which converts DAG to PA [59]. In this study, increased DAGK activity was 
observed following an increase in PI(3,4,5)P3 and PI(3,4)P2 both in vitro and in vivo. 
This was an interesting result as it was the first instance of DAGK activation in the 
absence of receptor-regulated calcium release. Further, it showed that DAGK can be 
activated and recruited to the plasma membrane as a direct consequence of PI3K 
activation highlighting the interconnectivity of lipid metabolic pathways [59].  
 Interestingly, another study showed extended inhibition of PI3K resulted in 
increased expression level of DAGK, contradictory to the previously described study. 
DAGK has been shown to activate tyrosine kinase SRC, which canonically is activated 
through PIP3/Akt [22, 60]. Dual inhibition of both DAGK and PI3K leads to a decrease in 
cell growth versus a single agent inhibition alone. These results suggest that 
understanding pathway heterogeneity and the changes oncogenic mutations confer as 
well as the relationship between the other enzymes and metabolites within the PI3K 
pathway are essential to achieving clinical success targeting the PI3K pathway or other 
members of the PI metabolic network [6, 22, 61]. Likewise, the seemingly contradictory 
actions of the pathway under different cell stimuli and in different cell types could be 
vital to understanding the pathway’s contributions to disease progression. Thus, an 
improved understanding of the direct role of PIs in disease progression would further 
validate this pathway as a drug target and lead to improved understanding of the 
interplay between the pathway’s metabolites, lead to biomarker identification, and serve 
as a powerful tool in achieving clinical success targeting the pathway.  
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1.5 Measurement of Lipid Metabolites 
1.5.1 Background  
 To better understand the systems biology of PIP metabolism, sensitive detection 
methods are needed to analyze the changes of both major and minor metabolites. Such 
sensitivity is necessary to discern the roles of low-level metabolites in the system and to 
extend the analysis to a single cell level to in order to paint a clear picture of the tumor 
microenvironment[34]. PIPs represent less than 1% of total phospholipid content in the 
cell and at a concentration of 10 mM PIP2 is 25-fold more abundant than other 
phosphorylated PI metabolites [21, 23]. Sensitive and robust detection methods are 
needed for analysis, especially when only a maximum of 10% of this pool of PIP2 is 
converted to PIP3 following stimulation and the metabolite has a short life span [25, 62-
64].   
1.5.2 Radiolabeled Substrate 
 Current methods aimed at quantifying PI metabolism is done using radioactivity-
based methods through the metabolic labeling of living cells with radiolabeled inorganic 
phosphate (32Pi or 33Pi) or [2-3H]myo-inositol. A major downfall of this method is that 
labeling time and conditions greatly affects signal output and can therefore result in 
improper analysis of metabolic activity. This method also suffers from the inability to 
distinguish phosphorylation isomers such as PI(4,5)P2 vs. PI(3,4)P2 and requires a large 
number of cells for analysis and therefore is ineffective at analysis of tumor 
microenvironment heterogeneity through single cell analysis [20, 34, 62, 63]. These 
methods have been effective at quantifying the average basal levels of multiple 
metabolites, though such a method takes long incubation (up to >24 h) and again lacks 
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sensitivity to effectively measure systematic metabolism. Likewise, while it is acceptable 
for studying steady-state metabolism of PIs it is not effective in accurately capturing 
short lived metabolic products such as PIP3 [34]. Because of the drawbacks of this 
method, it would not be effective in achieving a detailed view of PI metabolism 
necessary for use in diagnostic applications. 
1.5.3 Mass Spectrometry 
 Mass spectrometry (MS) can also be used to analyze complex mixtures of 
PtdIns metabolites. Unfortunately MS relies on a large number of cells and can be 
problematic in identifying low level and highly phosphorylated phospholipid species 
such as PI(4,5)P2 and PI(3,4,5)P3 [64-68]. A promising MS method requires chemical 
manipulation of isolated phospholipids in a reaction with TMS-diazomethane to 
generate a pool of methylated phosphate esters [64, 67]. This neutralizes the negative 
charge of the lipid and allows for a more sensitive detection on MS. Following parent ion 
identification, a MS/MS experiment can be performed to determine the phosphorylation 
state of the selected mass by fragmentation and analyzing for the mass of the now 
neutral inositol head group. While this method is successful in determining the relative 
concentration of lipid metabolites in a cell population, it is unable to distinguish isomers 
of phosphorylation states and using the endogenous pool of lipids results in a large 
number of mass signals that must be analyzed. Likewise, the PIs can contain various 
fatty acids at the sn-1 and 2 positions further complicating analysis, though such 
detailed information may be useful when further analyzing the role of PI metabolites in 
biological processes [64, 66, 67]. This method is also very technically demanding with 
complex data analysis following the use of specialized MS equipment and methods [65, 
69].   
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1.5.4 Fluorescent Protein Domains 
 Another method of studying PI metabolism is the use of engineered fluorescent 
proteins such as tagged PH domains to analyze enzymatic activities via microscopy and 
the translocation of the fluorescent domains following cell stimulation. PH domains, 
such as that from Akt, are engineered to contain a green fluorescent protein (GFP) that 
can be monitored via fluorescence microscopy. Following a cell stimulation event, the 
fluorescent domains can be analyzed translocating form the cytosol to the membrane 
where the lipid messenger is present [70]. Such methods, however, are indirect 
measurements of enzymatic activity and suffer from the inability to analyze multiple 
metabolites simultaneously [34, 62, 71, 72]. Likewise, it has been demonstrated that PH 
domains can bind to multiple lipid metabolites again complicating biological conclusions 
that could be discerned from using this method. Further, this method cannot be used as 
diagnostic tool because of the necessity to engineer and express fluorescent-tagged 
protein domains is not compatible with clinical samples [20, 62, 63].  
1.6 Synthetic Tools for Studying PIP Metabolism 
1.6.1 Fluorescent Substrates 
 A promising tool for the advancement of PIs analysis are synthesized reporters 
that share the core structure of specific PI metabolites while containing unique chemical 
moieties that allows for sensitive and specific quantification of metabolites [20]. Such an 
approach is powerful because the reporters can be manipulated to contain various 
moieties specific to the desired biological question. One of the most widely used 
chemical biology methods that have been increasingly applied to synthetic PIs is the 
use of a fluorescent-tagged substrate. This technology allows for visualization of the PI 
metabolic network by both microscopy as well as monitoring biochemical reactions via 
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thin layer choromatography (TLC) separation and fluorescent scanning [71]. Such a 
technology is more advantageous than radiolabeling due to increased sensitivity of 
fluorescence based analytical platforms. Likewise, a known concentration of a specific 
metabolite reporter could be loaded into cells versus relying on the steady-state 
metabolic incorporation of the labeled unit into the pool of phospholipids allowing for the 
direct dissection of specific nodes of the metabolic pathway and possibly systematic 
metabolic analysis. Fluorescent PIP reporters have been shown to serve as substrates 
for various PI modifying enzymes in-vitro, but due to the difficulty in their chemical 
synthesis, there has been little analysis on the effects of reporter structure on enzymatic 
turnover or cellular localization[62, 63, 71, 73]. 
1.6.2 Chemical Cytometry coupled with Fluorescent Substrates 
 Another trend in PIP systems biology is the use of microanalytical chemical 
separation, known as chemical cytometry, to separate and analyze complex cellular 
mixtures. One such technique, capillary electrophoresis with laser-induced fluorescence 
(CE-LIF), has been validated as an effective platform for analyzing multiple classes of 
lipid kinases and phosphatase reporters and is capable of single cell metabolic analysis 
[62, 74-78]. Further, this method has been validated for the separation of the various 
metabolites found within the PIP metabolic network, including isomers of the same 
phosphorylation state [62, 63]. In this method, cells are loaded with fluorescent 
reporters followed by lysis of the cells and the contents are loaded into a capillary and 
separation is achieved via capillary electrophoresis. This method holds great promise 
for PIP metabolic analysis as a known concentration of reporter can be delivered to the 
cell to minimize perturbation of the endogenous pool of metabolites. The level of 
sensitivity, as low as 10-20 mol, and the capability of single-cell analysis also makes this 
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a powerful technique for developing a lipid profile and could also be applied to patient 
samples for possible diagnostic applications [62, 63, 77]. Such technology could be 
applied to PI metabolic analysis and provide a detailed profile of PIP metabolites in 
various disease states and provide a powerful system to better understand the systems 
contributions to biology. Ideally, a fluorescent reporter could be delivered to cells where 
it could undergo in-cell mixture synthesis through the metabolic network followed by 
analysis of the collective of lipid metabolites by CE-LIF as shown in Figure 1.5. In this 
dissertation, I will describe our efforts in validating a platform utilizing fluorescent lipid 
reporters for PIP metabolic analysis.  
 
  
	
Figure 1.4 Systematic Analysis of Cellular PIP Generation: A system 
using a validated fluourescent PIP2 reporter coupled with non-invasive 
delivery techniques would allow for generation of a variety of fluorescent 
metabolites that can then be measure via CE-LIF and TLC 
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CHAPTER 2. THE IMPORTANCE OF HYDROPHOBICITY IN LIPID SIGNALING 
REPORTERS: SYNTHESIS AND EVALUATION OF FLUORESCENT LIPID 
REPORTERS 	
2.1	Introduction	to	Interfacial	Catalysis	by	PIP	Modifying	Enzymes	
 
PI3K and other PIP modifying enzymes catalyze reactions at the lipid/water 
interface in a process known as interfacial catalysis wherein hydrophobic contact 
between the enzyme and substrate as well as enzyme and membrane are of critical 
importance to catalytic turnover [46, 79, 80]. Likewise, various cancer causing mutations 
in the PIP family of enzymes have been shown to cause increased activity through 
required hydrophobic interaction with the membrane [46, 80] Consequently, the 
hydrophobic side chains in fluorescent PIP derivatives will likely play important roles in 
their capacity as enzyme substrates. Consequently, reporters that cannot undergo 
efficient metabolism like that of their endogenous counterparts will not be useful tools in 
monitoring cellular PIP metabolism [20]. 
  Unfortunately PIP synthesis is labor intensive and consequently short chain 
soluble PIPs are more frequently utilized as they are easier to synthesize, purify and 
analyze in biochemical assays [81, 82]. However, the effects of the acyl chain in these 
fluorescent PIPs on their capacity as enzyme substrates have been ignored. The roles 
of the side chains in non-fluorescent substrates have been previously demonstrated. 
For example, a study of B. cereus phospholipase C (PLC) activity on 
phosphatidylcholine substrates revealed changes in the kinetic constants for the various 
substrates with a preference for long acyl chains [83].  
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With the goal of using fluorescent PIP reporters to profile cellular metabolism we 
synthesized fluorescent PIP2 and PtdIns derivatives that contain varied degrees of 
hydrophobicity and investigated their ability to serve as reporters of PI3KIα and PI4KIIα 
activity, respectively. This chapter describes the synthesis and biochemical evaluation 
of various PIPs with different degrees of hydrophobicity in their side chains for selection 
of a suitable reporter for cellular studies. We describe a set of assays that prove useful 
in reporter selection for lipid signaling enzymes and could be applied to various classes 
of signaling phospholipids. We further describe the synthesis of various other PIP 
metabolites based on our finings in these studies to be used as both standards and 
reporters in future cellular experiments. 
2.2 Results and Discussion 
2.2.1 Design and synthesis of fluorescent PIP2 derivatives 
To investigate the effects of hydrophobicity on the capacity of fluorescent PIP2 
derivatives as enzyme substrates, we synthesized four PIP2 analogs PIP2-C6, PIP2-C9, 
PIP2-C12 and PIP2-C15 with different alkyl groups C6H13, C9H19, C12H25, and C15H31, 
respectively, at the sn-2 position according to Scheme 2.1.  Fluorescein was chosen as 
the fluorophore for evaluation of multiple PIP2 derivatives because of our prior success 
in separating fluorescein-tagged PIPs by both thin layer chromatography (TLC) and 
capillary electrophoresis (CE) [62, 71, 76]. A BODIPY tagged C15 PIP2 was (BODIPY-
C15-PIP2) also synthesized as the fluorophore possesses some chemical 
characteristics that may make it a more suitable for cellular analysis [84]. Briefly, 
carboxylic acids 1 with various length of alkyl chain coupled with the alcohol 2. 
Subsequently, the p-methoxybenzyl (PMB) group was removed to form 3. The primary 
alcohol in 3 was then converted to a phosphoramidite, which was coupled to the 
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protected inositol 4 previously synthesized according to literature protocols [81]. After 
oxidation with t-butyl hydroperoxide, compound 5 was formed and the carboxybenzyl 
(Cbz) and benzyl (Bn) groups were removed by hydrogenolysis. Deprotection of the 
methoxymethyl (MOM) groups then provided the primary amine 6, which reacted with 
the NHS ester of fluorescein 7 or BODIPY 9 to yield fluorescent PIP2 derivatives [81, 82, 
85, 86]. 
 
BODIPY-PtdIns-C15 was synthesized in a similar manner according to 
according to Scheme 2.2 [81]. Briefly, DAG phosphoramidite 12 containing palmitic acid 
at the sn-2 position was synthesized as described in Scheme 2.1 and was coupled with 
protected inositol derivative 11 followed by oxidation with t-BuOOH to generate 
	
Scheme	2.1:	Synthesis	of	Fluorescent	PIP2	Derivatives	with	Varied	
Hydrophobicity	
	21	
compound 13. Removal of all the protective groups resulted in 14, which reacted with 
BODIPY-NHS to provide fluorescent 15 (BODIPY-PtdIns-C15).  
 
 
2.2.2 Biophysical and Biochemical Evaluation of Fluorescent PIP2 Reporters 
The critical micelle concentration (CMC) of the fluorescent PIP2 derivatives was 
calculated by measuring light scattering of various concentrations of the reporters in 
H2O at 25 °C [71]. As expected, the PIP2 derivative with a longer acyl chain, and 
thereby higher hydrophobicity, has lower CMC value than that with a shorter acyl chain 
In comparison, the endogenous PI(4,5)P2 has a reported CMC of 10 µM [71].  
A mixed micelle assay was utilized to compare the kinetic parameters of the 
substrates [71]. The assay was initiated by the addition of purified PI3K enzyme to 
assay buffer containing individual fluorescent PIP2 derivative and ATP and stopped by 
the addition of a mixture of CHCl3/MeOH (1:1 v:v). The reaction mixture was analyzed 
	
Scheme	2.2:	Synthesis	of	Fluorescent	PtdIns	Reporter		
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by TLC or CE for production of fluorescent PI(3,4,5)P3 as previously described [71]. The 
concentration of substrate was varied to give a set of initial velocity values and this data 
was fit to the Michaelis-Menten equation to calculate the relative Km and Vmax values of 
the reporters summarized in Figure 2.1. Under these conditions, no detectable amount 
of the corresponding PIP3 was formed for the PIP2-C6 reporter, suggesting that short 
chain PIP2-C6 was not an effective substrate for PI3KIα under the assay conditions 
examined. Unsurprisingly, the most hydrophobic PIP2-C15 was the most efficiently 
metabolized substrate.  
 
To further assess the ability of fluorescent PIP2 probes as PI3KIα substrates, a 
1:1 (mol:mol) mixture of PIP2-C9 and PIP2-C15 was used in a mixture in a soluble PI3K 
assay, with reactions of equimolar PIP2-C9 or PIP2-C15 alone under the same assay 
conditions as controls. PIP2-C9, PIP2-C15 and their corresponding PI(3,4,5)P3 products 
were efficiently separated by CE (Fig. 2.2 B). As shown in Figure 2.2, the conversion of 
PIP2-C9 in the presence of PIP2-C15 was decreased by approximately 5-fold compared 
	
Figure 2.1: Critical Micelle Concentration (CMC) and Kinetic 
Constants of PIP2 Derivatives. The CMC was measured in water using 
dynamic light scattering (DLS). Mixed micelle PI3K assays were used to 
calculate the kinetic constant of the various fluorescent derivatives. Kinetic 
constants for the C6 reporter were not obtained due to the lack of 
production of the corresponding PIP3. 
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to when it was the only PI3K substrate. In contrast, the conversion of PIP2-C15 
remained consistent with or without the presence of PIP2-C9. These results again 
highlight the importance of hydrophobicity in fluorescent PIP2 probes, especially when 
competing substrates were present- a scenario when the probe was used as a reporter 
in live cells. 
 
A.	
	B	
	
Figure 2.2 Fluorescent PI(4,5)P2 Substrate Competition. (A) Mixed 
micelle PI3K assay conditions were used to analyze the effects of 
multiple reporters in solution. Production of PIP3 was monitored from 
reactions that contained a single fluorescent PIP2 derivative (20 µM), 
short chain C9 or long chain C15, as well as production of each product 
in reactions that contained both reporter in equimolar (20 µM) 
concentrations. (B) Representative chromatogram of separation of PIP2-
C9, PIP2-C15, PIP3-C9 and PIP3-C15 by CE. The CE analysis was 
carried out by Dr. Angela Proctor in Dr. Nancy Allbritton’s lab				
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2.2.3 In vitro Membrane Association of Fluorescent PIP2 Reporters 
The acyl side chain in a fluorescent PIP2 probe is vital to cellular localization. 
However, the non-invasive method of using histone as a carrier protein to deliver 
fluorescent PIP2 derivatives into cells resulted in very low efficiency in our hands [87]. 
Consequently, we utilized a membrane association assay that was developed for 
protein-lipid interactions to investigate likely membrane localization of fluorescent PIP2 
probes [88]. In this assay, liposomes and the associated cargo are recovered by 
centrifugation atop a dense sucrose gradient. Liposomes were formulated to mimic 
mammalian membranes with a final composition of phosphatidylcholine (PC; 45%), 
phosphatidylethanolamine (PE; 25%), phosphatidylserine (PS; 5%), phosphatidylinositol 
(PtdIns; 10%), and cholesterol (Chol; 15%). Figure 2.3 shows representative images of 
the assay mixtures after centrifugation. The top lipid layer and bottom sucrose layers 
were then collected and each layer quantified by CE for the presence of fluorescent 
PIP2. Approximately 91% of the PIP2-C15 probe was incorporated into the liposome 
layer (Fig. 2A). The percentage of incorporation decreased dramatically to 35% for 
PIP2-C12. Only 12% and 9% of the probe was incorporated into liposome for PIP2-C9 
and PIP2-C6, respectively. These results demonstrated that only the PIP2-C15 probe 
with a long acyl side chain could be efficiently incorporated into membrane like 
structures, which is important for localization if these reporters are to be used in future 
cellular experiments.  
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2.2.4 Vesicle Based PI3K Analysis 
To further assess whether PIP2-C15 functions as an effective reporter in the 
presence of endogenous substrate, the PI3K-catalyzed reaction was run on lipid 
vesicles, an environment that closely mimic cellular presentation of lipid substrates, in 
the presence or absence of endogenous PIP2. Liposomes composed of a carrier lipid, 
phosphatidylserine (PS) which is the most commone anionic lipid in the plasma 
membrane, PIP2-C15 and endogenous PIP2 at different ratios, were formulated for 
enzymatic reactions [39, 89]. The total concentration of PIP2-C15 and endogenous PIP2 
was 10 µM, which is close to that of the cellular environment and the conversion of 
PIP2-C15 to its corresponding PIP3 product was then measured and shown in Figure 
2.4. The rate of conversion decreased by approximately 27% when the ratio of PIP2-
C15 to endogenous PIP2 was 1:1, and approximately 50% when the ratio was 1:9, 
	
Figure 2.3: In-vitro Membrane Association of Fluorescent PIP2 
Reporters: Probes were incubated with liposomes and under a 
gradient of sucrose. Following centrifugation the samples were 
visualized using a UV light source. The top liposome containing layer 
and bottom layer weas isolated and total PIP2 content was 
determined using CE separation.  
	26	
compared to 100% PIP2-C15. These results suggested that PIP2-C15 was a similar to 
endogenous substrate and can function as a reporter of PI3K activity.  
 
2.2.5 Required Hydrophobicity for PI4K Substrate PtdIns 
Like PI3K, PI4K catalyzes reactions at the lipid/water interface. Consequently, 
what was observed for PI3K likely applies to PI4K as well as other enzymes in the 
pathway. There is only one commercial fluorescent PI derivative, BODIPY-PtdIns-C7 
(Fig. 2.5A) with a short acyl side chain. We thus designed BODIPY-PtdIns-C15 with a 
longer acyl side chain to assess its capacity as PI4K substrate. Next, both BODIPY-
PtdIns-C15 were BODIPY-PtdIns-C7 tested as substrates of PI4KIIα under soluble 
assay conditions. Consistent with what we observed with fluorescent PIP2 derivatives, 
the PI(4)P product of the fluorescent PI with a longer acyl side chain BODIPY-PtdIns-
C15 was efficiently generated shown in . In contrast, no detectable amount of product 
was formed for BODIPY-PtdIns-C7 containing a shorter acyl side chain shown in 
	
Figure 2.4: Competition with Endogenous PI(4,5)P2 in Liposome Based 
Assay: Liposomes were formulated to contain 10 µM total PI (4,5)P2 using 
fluorescent C15 PI(4,5)P2 derivative or endogenous PI(4,5,)P2 and 10 µM of 
PS as a carrier lipid. Production of Pi(3,4,5)P3 was monitored to analyze the 
ability of the reporter to be metabolized in the presence of endogenous 
substrate. 
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Figure 2.5B. Likewise, over 99% of BODIPY-PtdIns-C15 (not detectable in the 
aqueous layer) but only approximately 15% of BODIPY-PtdIns-C7 participated into the 
lipid layer in the in vitro membrane association assay as seen in Figure 2.5C.  
 
 
2.2.6 Synthesis of BODIPY-DAG-C15 and BODIPY-PA-C15 
With the goal of using these reporters for future cellular studies, multiple lipid 
metabolites of the PIP pathway for were also synthesized as standards for metabolite 
identification.  BODIPY-DAG-C15 and BODIPY-PA-C15 were synthesized to contain 
the C15 acyl chain to be used as standards for CE and TLC analysis of cellular 
experiments as well as chemical reporters.  In addition to the C15 alkyl chain, the 
	
Figure 2.5: Biophysical and Kinetic Analysis of Fluorescent 
PtdIns Analogs: A. Chemical structures of fluorescent PtdIns 
derivatives. B. Mixed micelle PI4K assay with fluorescent PtdIns 
derivatives monitoring production of PtdIns(4)P. C. Representative 
images of fluorescent PtdIns derivatives interacting with liposome 
with fluorescent PtdIns quantified by CE separation. 	
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metabolites were synthesized also contain the same N-caproic acid tagged with a 
BODIPY fluorophore was kept constant to ensure the standards will chemically match 
the metabolites produced from our reporter in cellular experiments. When synthesizing 
fluorescent DAG, great care must be taken to avoid acyl migration from the secondary 
sn-2 position to the primary sn-3 position of DAG. If the primary hyrdroxyl is free under 
hydrogenolysis and basic conditions the side chain will migrate. To alleviate this, the 
hydroxyl was left protected with a PMB group until the final deprotection with DDQ. 
Under these conditions acyl migration does not occur as judged by NMR analysis of 
products from each synthetic step. Briefly, the Cbz group is selectively deprotected via 
hydrogenolysis in the presence of pyridine leaving the PMB group intact [90, 91]. 
Addition of BODIPY via the corresponding NHS ester followed by DDQ oxidation of the 
PMB protecting group resulted in final fluorescent DAG (Scheme 2.3A). Fluorescent PA 
was synthesized in a scheme similar to PIP2 and PtdIns synthesis because the hydroxyl 
is phosphorylated in acidic conditions there is much less concern for acyl migrations. 
Briefly, compound 3d was phosphorylated using commercial phospohramidite as 
previously described. Hydrogenolysis of the Cbz and Bn protecting groups and 
subsequent addition of NHS-BODIPY resulted in pure fluorescent PA (Scheme 2.3B).  
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2.3 Conclusions and Future Directions 
In summary, we have synthesized a series of fluorescent PIP2 derivatives with 
varied levels of hydrophobicity and investigated their capacity as PI3K substrates. The 
probe with a longer acyl side chain functions as a better substrate for PI3K and has a 
higher affinity with liposome compared to that with a shorter acyl side chain. Strikingly, 
when the side chain is sufficiently short and thereby has low hydrophobicity, the 
fluorescent PIP2 is no longer an effective PI3K substrate to generate detectable amount 
A.	
	B.	
	
Scheme 2.3: Synthesis of PIP Metabolites. A. Synthetic scheme for the 
synthesis of fluorescent diacylglycerol (DAG). B. Synthetic scheme for the 
synthesis of fluorescent phosphatidic acid (PA) 
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of enzymatic product, highlighting the required hydrophobicity of fluorescent PIP2 
derivatives. Likewise, the fluorescent PtdIns derivative with a long acyl side chain 
functions as an effective PI4K substrate, while that with a short acyl side chain does not 
generate detectable amount of enzymatic product. These results suggest that the 
required hydrophobicity of a fluorescent probe, which can be assessed through its 
interaction with liposomes, is likely essential for phosphatidylinositide metabolic 
enzymes.  
PIP2-C15 has shown similar properties as the endogenous PIP2 in regard to 
CMC, kinetic parameters and tendency for membrane association. Unlike the 
endogenous PIP2, PIP2-C15 is easy to handle both in chemical synthesis and CE 
separation. Similarly, BODIPY-PtdIns-C15 has also been efficiently synthesized and 
separated from its enzymatic products. These results demonstrate that fluorescent 
PIP2-C15 and PtdIns-C15 may strike the right balance between required hydrophobicity 
and practical handling during chemical synthesis and separation. Consequently, they 
are likely effective fluorescent probes that can be used to profile metabolism of PIPs 
when coupled with CE separation. Likewise, fluorescent PI, DAG and PA will serve as 
valuable standards for analyzing PI metabolism as well as serve as functional tools for 
dissecting distinct nodes of the PI metabolic pathway.  When coupled with an effective 
cellular delivery method, and CE separation, we predict these reporters will be capable 
of monitoring changes in dynamic PI metabolism. 
With the ultimate goal of the work being cellular analysis of PIs, the cellular 
efficacy of the lipid reporters must be confirmed using an effective delivery method and 
analysis for metabolic distribution of metabolites. Ideally, our system will mimic closely 
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what has been previously described using radiolabeled substrates, though with 
increased sensitivity for minor metabolites.  Despite our best efforts at analyzing 
membrane association via a liposomal flotation experiment, it is still possible we will see 
non-specific and cytosolic localization of our lipid reporters. Therefore, it may be 
beneficial to further increase the hydrophobicity at the sn-2 position of the PI reporters. 
One such modification would be the addition of stearic, nonadecyclic, or arachidic acids 
at this position to further increase hydrophobicity and better mimic the endogenous 
substrate. Likewise, removal of the fluorophore for an alkyne tag on all substrates would 
make the reporters more suitable for cellular delivery and could lend well to future 
analytical platforms of single cell analysis. Further, the fluorophores of various PI 
metabolites could be altered to allow multiple pools of metabolites to be tracked 
distinctly by using dual fluorophores with unique and non-overlapping excitation 
wavelengths. 
2.4 Experimental 
PIP2-C12 and related intermediates were synthesized and characterized by Dr. 
Weigang Huang. Purified PI3KIα enzyme was purchased from Invitrogen-Life 
Technologies. Purified PI4KIIα was purchased from Creative Biomart. Dynamic light 
scattering data were recorded on a Wyatt DynaPro dynamic light scattering plate 
reader. Endogenous PI(4,5)P2 (brain, porcine) was purchased from Avanti Polar Lipids. 
PtdIns-C7 was purchased from Echelon Biosciences and confirmed via ES-HRMS 
(Appendix). ATP and TLC plates with silica gel 60 were purchased from Sigma. All 
solvents were purchased from Fischer Scientific. NMR analysis was done on an Inova 
400 MHz spectrometer in the indicated solvent- spectra are available in the Appendix. 
All compounds were further confirmed by ESI mass spectrometry. 
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2.4.1 Soluble PI3K Assay Conditions  
Fluorescent PIP2 derivatives were added to assay buffer composed of MOPS (50 mM, 
pH 6.7), NaCl (100 mM), MgCl2 (10 mM), sodium cholate (0.5 mM), DTT (1 mM), 
followed by the addition of ATP (2 mM). The reaction was initiated by the addition of 
purified PI3Kiα enzyme to a final concentration of 1.2 ng/µL or 2.4 ng/µL and incubated 
at 37 °C. At the indicated time point, an aliquot of the reaction was removed and diluted 
to 0.2 µM in CHCl3/MeOH (1:1) for analysis. All assays were performed in duplicate 3 
times. 
2.4.2 Soluble PI4K Assay Conditions  
Fluorescent PtdIns derivatives were added to assay buffer composed of MOPS (50 mM, 
pH 6.7), NaCl (100 mM), MgCl2 (10 mM), sodium cholate (0.5 mM), DTT (1 mM), 
followed by the addition of ATP (2 mM). The reaction was initiated by the addition of 
purified PI4KIIa enzyme to a final concentration of 1.0 ng/µL and incubated at 37 °C. At 
the indicated time point, an aliquot of the reaction was removed and diluted to 0.2 µM in 
CHCl3/MeOH (1:1) for analysis. All assays were performed in duplicate for 3 times. 
2.4.3 Vesicle Based PI3K Assay Conditions  
Liposomes were prepared to contain 10 µM total PIP2 composed of PIP2-C15 and 
endogenous substrate with 10 µM phosphatidylserine (PS) as a carrier lipid in final 
assay conditions. Lipid stocks in CHCl3 or water were added to a 1:1 MeOH/H2O 
mixture followed by solvent removal by speed-vac and drying under vacuum for at least 
1 h. The lipids were then re-suspended in 5X MOPS (250 mM, pH 6.7) and 5X NaCl 
(500 mM) followed by sonication in a bath for 5 min to form lipid vesicles. The vesicles 
were then used to prepare a mixture containing a final PtdIns(4,5)P2 concentration of 10 
µM in MOPS (50 mM, pH 6.7), NaCl (100 mM), DTT (1 mM), MgCl2 (10 mM) and ATP 
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(2 mM). The reaction was initiated by adding purified PI3K enzyme (0.6 ng/µL) and then 
incubated at 37 °C. At the indicated time point, an aliquot of the reaction mixture was 
removed and diluted to 0.2 µM in 1:1 CHCl3/MeOH for TLC analysis. In the case of the 
10% PIP2-C15 liposome, the reaction was first stopped by the addition to methanol, 
followed by concentration and addition of CHCl3/MeOH to achieve the desired 
concentration of 0.2 µM FL-PtdIns(4,5)P2 substrate as direct dilution results in phase 
separation. All experiments were performed using a single batch of liposome in 
duplicate for three times. 
2.4.4 TLC Analysis of Fluorescent Lipid Metabolites  
TLC plates (Merck, Silica Gel-60) were pre-treated with a solution of 1.2% potassium 
oxalate and 1.2 mM EGTA in MeOH/water (v:v = 2:3) and heated at 110 °C for 20 min 
before use. Reaction mixture was diluted in CHCl3/ MeOH (v:v = 1:1) and spotted on a 
TLC plate directly. The TLC plate was then developed in 
CHCl3:Acetone:MeOH:AcOH:water (v:v:v:v:v = 80:30:26:24:14) and scanned on a 
Typhoon 9400 Variable Mode Imager (lex/lem = 488 nm/520 nm). The fluorescence 
intensity of various spots on the TLC plate was quantified with ImageQuant software 
(V.5.0). 
2.4.5 CE Analysis of Fluorescent Lipid Metabolites  
Capillary electrophoresis coupled with laser induced fluorescence detection (CE-LIF, 
488 nm excitation) was performed on a custom-built system mounted to the stage of an 
inverted microscope, described previously in detail[75]. Fused silica capillaries were 38 
cm long with a 20.5 cm effective length [30 µm inner diameter and 360 µm outer 
diameter (Polymicro Technologies; Phoenix, AZ)] and were conditioned prior to use by 
rinsing for 1 h in DI H2O, 12 h in 0.1 M NaOH, 1 h in DI H2O, 6 h in 0.1 M HCl, and 12 h 
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in DI H2O. Prior to each run, capillaries were rinsed with 1 M NaOH and DI H2O for 5 
min each and with electrophoretic buffer for 10 min by application of pressure to the 
capillary outlet. Buffer at the capillary inlet and outlet was completely refreshed prior to 
each electrophoretic run. The composition of the electrophoretic buffer was 80 mM 
NaH2PO4, pH 6.8 containing 15% 2-propanol and a field strength of 210 V cm-1 was 
used for all separations. Internal standards and samples were hydrodynamically loaded 
by raising the inlet 3 cm relative to the outlet and holding the capillary inlet in the sample 
for 10 sec. The inlet was then lowered to the height of the outlet and electrophoresis 
was initiated by application of a negative voltage to the outlet while grounding the inlet. 
Electropherograms were plotted and analyzed utilizing OriginLab 9.0 (OriginLab 
Corporation; Northampton, MA). 
2.4.6 Fluorescent lipids/liposome interaction 
The liposome mixture was prepared from stock solutions of lipids in CHCl3 for a final 
composition of 45% PC, 25% PE, 15% cholesterol, 10% PI, and 5% PS. The solvent 
was blown off under a stream of N2 followed by drying under vacuum for at least 1 h. 
The lipid film was then suspended in buffer composed of MOPS (50 mM, pH 6.7), NaCl 
(100 mM), DTT (1 mM), and MgCl2 (10 mM) to a concentration of 2 mM. Liposomes 
were extruded through a 0.03 µM pore size polycarbonate filter membrane for at least 
11 times back and forth. Fluorescent PIP2 or PI (10 µM) and liposomes (1 mM) were 
incubated in buffer at room temperature for 5 min in a total volume of 150 µL. The 
suspension was adjusted to 30% sucrose by the addition of 100 µL of 75% w/v sucrose 
in buffer followed by mixing. Buffer (200 µL) containing 25% w/v sucrose was then 
overlaid on the high-sucrose suspension followed by 50 µL of buffer containing no 
sucrose. The sample was centrifuged at 55,000 r.p.m in a Beckman swing rotor (TLS 
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55) for 1 h at 4 °C. The bottom 350 µL and top 150 µL were manually collected using a 
syringe and analyzed for fluorescent PI or PIP2 content by both TLC and CE. A 
fluorescence image of the tubes was also taken prior and following centrifugation using 
a UV light source below the samples and a CCD camera. 
2.4.7 Chemical Synthesis  
Synthesis of (S)-1-((6-(((benzyloxy)carbonyl)amino)hexanoyl)oxy)-3-
hydroxypropan-2-yl palmitate 3d) A mixture of compound 2  (350 mg, 0.76 mmol), 1d 
(234.5 mg ,0.91 mmol), DCC (189 mg, 0.91 mmol), and DMAP (51 mg, 0.42 mmol) in 
anhydrous CH2Cl2 (6 mL) was stirred at room temperature overnight. The reaction 
mixture was concentrated and purified by flash chromatography (hexane-ethyl acetate = 
2:1) over silica (407 mg, 89%). The so-formed intermediate (407 mg, 0.58 mmol) was 
dissolved in wet CH2Cl2 (20 mL) followed by addition of DDQ (278 mg, 1.2 mmol) and 
the mixture was stirred at room temperature for 4 h. The reaction mixture was then by 
washed with 10% NaHCO3 and saturated NaCl, dried over MgSO4, and concentrated 
under vacuum. The residue was then purified by flash chromatography (hexane-ethyl 
acetate =2:1) over silica to generate 3d (281 mg, 83%) as a colorless oil. 1H NMR (400 
MHz, CDCL3) δ 7.26-7.38 (m, 5H), 5.06-5.11 (m, 3H), 4.83 (brs, 1H), 4.33 (dd, J = 11.9, 
4.5 Hz, 1H), 4.21 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 (d, J = 4.9 Hz, 1H), 3.19 (q, J = 13.1, 
6.7 Hz, 1H), 2.24-2.30 (m, 4H), 1.58-1.68 (m, 4H), 1.48-1.55(m, 2H), 1.25-1.38 (m, 
26H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ173.55, 156.58, 136.71, 
128.63, 128.21, 72.20, 72.12, 66.75, 62.30, 61.55, 40.94, 34.40, 33.99, 32.04, 29.82, 
29.78, 29.74, 29.60, 29.48, 29.39, 29.21. 26.23, 25.05, 24.55, 22.81, 14.24. ESMS 
577.8 [M]+ 
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Synthesis of (S)-1-((6-(((benzyloxy)carbonyl)amino)hexanoyl)oxy)-3-
hydroxypropan-2-yl tridecanoate (3c) Compound 3c (80 mg, 75%).  was prepared in 
a similar manner to compound 3d. 1H NMR (CDCl3, 400 MHz) δ 7.26-7.36 (m, 5H), 
5.02-5.15 (m, 3H), 4.96 (brs, 1H), 4.32 (dd, J = 11.9, 4.3 Hz, 1H), 4.18 (dd, J = 11.9, 5.9 
Hz, 1H), 3.69 (d, J = 5.2 Hz, 2H), 3.16 (q, J = 6.5 Hz, 2H), 2.26-2.36 (m, 4H), 1.43-1.66 
(m, 6H), 1.18-1.40 (m, 20H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 101 MHz) δ 
173.41, 173.37, 156.47, 136.57, 128.45, 128.03, 72.00, 66.56, 62.25, 61.27, 40.77, 
34.24, 33.82, 31.87, 29.61, 29.59, 29.57, 29.54, 29.30, 29.23, 29.05, 26.07, 24.89, 
24.39, 22.64, 14.08. ESMS 535.7 [M]+ 
 
Synthesis of (S)-1-((6-(((benzyloxy)carbonyl)amino)hexanoyl)oxy)-3-
hydroxypropan-2-yl decanoate (3b) Compound 3b (170 mg, 89%)  was prepared in a 
similar manner to compound 3d as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.26-
7.38 (m, 5H), 5.05-5.12 (m, 3H), 4.99 (brs, 1H) 4.33 (dd, J = 11.9, 4.2 Hz, 1H), 4.19 (dd, 
J = 11.9, 5.9 Hz, 1H), 3.70 (d, J = 5.1 Hz, 1H), 3.18 (q, J = 13.0, 6.5 Hz, 1H), 2.25-2.30 
(m, 4H), 1.46-1.56 (m, 6H), 1.20-1.39 (m, 14H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (101 
MHz, cdcl3) δ 173.11, 173.06, 159.29, 156.39, 136.65, 129.73, 129.28, 128.46, 128.04, 
128.02, 114.50, 113.79, 77.40, 77.08, 76.77, 72.92, 70.00, 67.86, 66.52, 62.81, 62.58, 
55.22, 55.11, 49.02, 40.81, 34.30, 34.08, 33.90, 33.84, 31.84, 29.67, 29.57, 29.41, 
29.25, 29.05, 26.13, 25.62, 24.93, 24.39, 22.64, 14.09. ESMS 493.2 [M]+ 
 
Synthesis of (S)-1-((6-(((benzyloxy)carbonyl)amino)hexanoyl)oxy)-3-
hydroxypropan-2-yl heptanoate (3a). Compound 3a was prepared in a similar manner 
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to compound 3d (336 mg, 0.73 mmol,  96%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.26-7.38 (m, 5H), 5.02-5.20 (m, 3H), 4.95 (brs, 1H), δ 4.33 (dd, J = 11.9, 4.3 
Hz, 1H), 4.20 (dd, J = 11.9, 5.8 Hz, 1H), 3.71 (d, J = 5.1 Hz, 2H), 3.18 (q, J = 6.5 Hz, 
2H), 2.25-2.38 (m, 4H), 1.40-1.75 (m, 6H), 1.19-1.40 (m, 8H), 0.88 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.12, 173.06, 159.29, 156.38, 154.12, 136.62, 129.73, 
129.28, 128.47, 128.06, 128.04, 113.80, 77.35, 77.03, 76.72, 72.93, 70.14, 69.99, 
67.86, 66.55, 62.82, 62.59, 55.24, 49.65, 49.18, 40.81, 35.93, 34.30, 33.84, 32.74, 
31.57, 31.42, 30.90, 29.67, 29.58, 28.93, 28.77, 28.70, 26.38, 26.13, 25.58, 25.50, 
25.42, 25.32, 24.88, 24.80, 24.70, 24.39, 22.47, 22.45, 14.01. ESMS 451.3 [M]+ 
Synthesis of tetrabenzyl ((1R,2R,3S,4R,5S,6S)-4-hydroxy-3,5,6-
tris(methoxymethoxy)cyclohexane-1,2-diyl) bis(phosphate) (4). 4 was synthesized 
as previously described from myo-inositol [81]. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.19 
(m, 19H), 5.15 – 4.87 (m, 11H), 4.84 (dd, J = 6.7, 0.9 Hz, 1H), 4.74 (dd, J = 6.6, 0.9 Hz, 
1H), 4.57 (dd, J = 7.1, 0.9 Hz, 1H), 4.53 – 4.34 (m, 4H), 4.16 – 4.12 (m, 1H), 3.74 (t, J = 
9.3 Hz, 1H), 3.64 – 3.54 (m, 1H), 3.50 – 3.44 (m, 1H), 3.42 – 3.39 (m, 3H), 3.30 – 3.28 
(m, 3H), 3.28 – 3.26 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 136.07, 136.04, 136.00, 
135.96, 135.93, 135.86, 128.51, 128.51, 128.49, 128.45, 128.41, 128.38, 128.32, 
128.27, 128.23, 128.15, 128.05, 128.00, 127.97, 127.89, 127.85, 127.77, 127.72, 99.00, 
97.65, 96.82, 83.27, 79.37, 79.32, 79.30, 79.26, 77.99, 77.94, 77.88, 77.48, 77.36, 
77.16, 76.84, 75.60, 75.09, 75.07, 75.05, 70.41, 69.58, 69.52, 69.49, 69.43, 69.24, 
69.19, 69.10, 69.01, 55.98, 55.78, 55.65, 55.55, 29.88, 29.85, 29.83, 29.81, 29.79. 31P 
NMR (162 MHz, CDCl3δ -1.37 (1P), -1.69 (1P). ESMS 832.3 [M]+ 
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Synthesis of (2R)-1-(((benzyloxy)(((1R,2S,3R,4R,5S,6R)-3,4-
bis((bis(benzyloxy)phosphoryl)oxy)-2,5,6-
tris(methoxymethoxy)cyclohexyl)oxy)phosphoryl)oxy)-3-((6-
(((benzyloxy)carbonyl)amino)hexanoyl)oxy)propan-2-yl palmitate (5d). 
A solution of 3d (100 mg, 0.17 mmol) in anhydrous CH2Cl2 (1 mL) was added drop-wise 
under argon to a flask that contained 1-(benzyloxy)-N,N,N’,N’- 
tetraisopropylphosphodiamine (360 mg, 0.43 mmol) and 1H-tetrazole (170 mg, 0.19 
mmol) in anhydrous CH2Cl2 (2 mL).  The mixture was stirred at room temperature for 2 
h and concentrated under vacuum. The resulting residue was purified by column 
chromatography (hexane:ethyl acetate:triethylamine = 100:20:3) to give a 
phosphoramidite intermediate as a colorless oil. The so-formed phosphoramidite (125 
mg, 0.15 mmol) in anhydrous CH2Cl2 (1.5 mL) was added to a solution of 4 (102mg, 
0.12 mmol) and 1H-tetrazole (82 mg, 0.30 mmol) in anhydrous CH2Cl2 (1.5 mL) under 
argon. The reaction mixture was stirred at room temperature overnight, followed by the 
addition of t-BuOOH  (5.5 M, 138 µL) at -40°C. The reaction was allowed to come to 
room temperature and stirred for 1 h followed by removal of solvents under vacuum and 
purified by flash chromatography (2:1 Hex:Acetone) to yield 85 mg of pure product and 
impure fractions. The impure fractions were then purified by HPLC (BETASIL C18 150 
X 21.2 mm water-acetonitrile 30 to 100% over 20 minutes 10 mL/min) to yield pure 
compound 5d (150 mg total, 70% combined from compound 3d) as a clear viscous oil.  
1H NMR (400 MHz, CDCl3) δ 7.38-7.26 (m, 30H), 4.80-5.21 (m, 14H), 4.80-4.60 (m, 
4H), 4.55 (d, J = 6.1 Hz, 1H), 4.05-4.49 (m, 9H), 3.53 (dd, J = 9.9, 10.1 Hz, 1H), 3.39 
(conformation 1) and 3.36 (conformation 2) (s, 3H), 3.32 (conformation 1) and 3.28 
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(conformation 2) (s, 3H), 3.24 (conformation 1) and 3.23 (conformation 2) (s, 3H), 3.17 
(q, J =6.4 Hz, 2H), 2.24-2.30 (m, 4H), 1.48-1.68 (m, 6H), 1.25-1.38 (m, 26H), 0.88 (t, J = 
6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173, 172.94, and 172.89 (1C), 156.55, 
136.80, 136.22, 136.17, 136.16, 136.09, 136.04, 135.64, 135.57, 128.83, 128.58, 
128.53, 128.15, 128.03, 98.96, 98.90, 97.66, 97.04, 78.91, 76.52, 75.90, 74.69, 69.68, 
69.62, 69.57, 69.52, 69.37, 69.32, 66.65, 66.55, 65.72, 65.54, 61.67, 56.80 and 56.74 
and 56.68 (1C), 56.02 and 55.93 (1C), 40.94, 34.18 and 33.84 (1C), 32.04, 29.81, 
29.61, 29.47, 29.41, 29.21, 26.27, 24.91, 24.49, 22.80, 14.24. 31P NMR (CDCl3, 162 
MHz) δ -1.31 (2P), -1.65 and -1.70 (1P) ESMS 1561.7 [M]+ 
Synthesis of (2R)-1-(((benzyloxy)(((1R,2S,3R,4R,5S,6R)-3,4-
bis((bis(benzyloxy)phosphoryl)oxy)-2,5,6-
tris(methoxymethoxy)cyclohexyl)oxy)phosphoryl)oxy)-3-((6-
(((benzyloxy)carbonyl)amino)hexanoyl)oxy)propan-2-yl tridecanoate (5c) 
Compound 5c (138 mg, 61%)  was prepared in a similar manner to compound 5d from 
3c (80 mg, 0.15 mmol) as a colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.18-7.40 (m, 30 
H), 4.80-5.22 (m, 14 H), 4.56-4.80 (m, 4H), 4.53 (d, J = 7.0 Hz, 1H), 4.02-4.46 (m, 9H), 
3.53 (dd, J = 10.0, 10.2 Hz, 1H), 3.37 (conformation 1) and 3.34 (conformation 2) (s, 
3H), 3.31 (conformation 1) and 3.27 (conformation 2) (s, 3H), 3.22 (s, 3H), 3.15 (q, J = 
6.3 Hz, 2H), 2.20-2.32 (m, 4H), 1.10-1.66 (m, 26H), 0.86 (t, J = 7.0 Hz, 3H); 13C NMR 
(CDCl3, 101 MHz) δ 172.83, 172.77 and 172.72 (1C), 156.41, 136.66, 136.07, 135.95, 
135.82, 135.57, 135.50, 135.43, 128.67, 128.43, 128.37, 128.28, 128.24, 128.18, 
128.00, 127.88, 98.81, 98.74, 97.61, 97.51, 97.42, 96.88, 78.76, 77.37, 77.24, 77.06, 
76.74, 76.35, 75.78, 74.53, 69.86, 69.81, 69.71, 69.64, 69.59, 69.53, 69.47, 69.42, 
	40	
69.36, 69.26, 69.21, 69.16, 66.48, 65.43, 61.52, 56.65 and 56 59 and 56.53 (1C), 55.85 
and 55.80 (1C), 55.76 and 55.69 (1C), 40.79, 34.03 and 33.69 (1C), 33.42, 31.89, 
29.66, 29.61, 29.60, 29.56, 29.45, 29.36, 29.32, 29.25, 29.05, 26.12, 24.76, 24.34, 
23.16, 22.65, 14.09; 31P NMR (CDCl3, 162 MHz) δ -1.37 (2P), -1.73 (1P). ESMS 1519.6 
[M]+ 
Synthesis of (2R)-1-(((benzyloxy)(((1R,2S,3R,4R,5S,6R)-3,4-
bis((bis(benzyloxy)phosphoryl)oxy)-2,5,6-
tris(methoxymethoxy)cyclohexyl)oxy)phosphoryl)oxy)-3-((6-
(((benzyloxy)carbonyl)amino)hexanoyl)oxy)propan-2-yl decanoate (5b) Compound 
5b (55 mg, 30% combined from 3b) was prepared in a similar manner to compound 5d 
from 3b (77 mg, 0.16 mmol) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.38-7.26 
(m, 30H), 4.81-5.21 (m, 14H), 4.60-4.79 (m, 4H), 4.55 (d, J = 6.1 Hz, 1H), 4.00-4.50 (m, 
9H), 3.50-3.58 (m 1H), 3.39 (conformation 1) and 3.36 (conformation 2) (s, 3H), 3.32 
(conformation 1) and 3.28 (conformation 2) (s, 3H), 3.24 (conformation 1) and 3.23 
(conformation 2) (s, 3H), 3.18 (q, J = 6.5 Hz, 2H), 2.18-2.34 (m, 4H), 1.40-1.70 (m, 6H), 
1.17-1.39 (m, 14H), 0.87 (t, J = 6.8 Hz, 3H). 31P NMR (CDCl3, 162 MHz) δ -1.31 (2P), -
1.66 and -1.71 (1P). 13C NMR (101 MHz, CDCl3) δ 172.82, 172.77, 172.72, 156.39, 
136.67, 136.13, 136.09, 136.05, 136.03, 136.01, 135.96, 135.91, 135.83, 135.58, 
135.51, 128.70, 128.67, 128.45, 128.43, 128.38, 128.35, 128.29, 128.24, 128.19, 
128.04, 128.00, 127.98, 127.93, 127.88, 98.81, 98.75, 97.52, 96.87, 77.34, 77.23, 
77.02, 76.71, 74.53, 69.85, 69.80, 69.71, 69.64, 69.58, 69.53, 69.47, 69.41, 69.36, 
69.28, 69.25, 69.21, 69.16, 66.49, 65.62, 65.38, 61.53, 56.62, 56.57, 55.85, 55.83, 
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55.74, 40.80, 34.04, 34.02, 33.70, 31.82, 29.66, 29.57, 29.39, 29.23, 29.04, 26.13, 
24.75, 24.35, 22.63, 14.08. ESMS 1477.5 [M]+ 
 
Synthesis of (2R)-1-(((benzyloxy)(((1R,2S,3R,4R,5S,6R)-3,4-
bis((bis(benzyloxy)phosphoryl)oxy)-2,5,6-
tris(methoxymethoxy)cyclohexyl)oxy)phosphoryl)oxy)-3-((6-
(((benzyloxy)carbonyl)amino)hexanoyl)oxy)propan-2-yl heptanoate (5a) Compound 
5a (20 mg, 20% combined from 3b) was prepared in a similar manner to compound 5d 
from 3a (80 mg, 0.18 mmol) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.38-7.20 
(m, 30H), 4.80-5.20 (m, 14H), 4.60-4.79 (m, 4H), 4.54 (d, J = 7.0 Hz, 1H), 3.99-4.50 (m, 
9H), 3.55 (t, J = 9.9, 10.0 Hz, 1H), 3.39 (conformation 1) and 3.36 (conformation 2) (s, 
3H), 3.32 (conformation 1) and 3.28 (conformation 2) (s, 3H), 3.24 (conformation 1) and 
3.23 (conformation 2) (s, 3H), 3.18 (q, J = 6.5 Hz, 2H), 2.20-2.35 (m, 4H), 1.37-1.81 (m, 
6H), 1.21-1.36 (m, 8H), 0.87 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.83, 
172.77, 172.72, 156.39, 136.12, 136.02, 135.95, 135.82, 128.71, 128.68, 128.66, 
128.45, 128.43, 128.38, 128.34, 128.29, 128.24, 128.19, 128.04, 128.00, 127.98, 
127.93, 127.88, 98.81, 98.75, 97.51, 96.87, 77.32, 77.00, 76.68, 74.53, 69.86, 69.80, 
69.71, 69.64, 69.52, 69.47, 69.41, 69.36, 69.21, 69.16, 66.51, 61.54, 56.62, 56.56, 
55.85, 55.83, 55.74, 40.80, 34.03, 34.01, 33.69, 31.89, 31.38, 30.89, 29.66, 29.57, 
28.67, 26.13, 24.70, 24.34, 22.42, 13.99. 31P NMR (CDCl3, 162 MHz) δ -1.32 (2P), -1.67 
and -1.72 (1P) ESMS 1435.5 [M]+ 
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Synthesis of (2R)-1-((6-aminohexanoyl)oxy)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-
2,3,6-trihydroxy-4,5-bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propan-2-
yl palmitate (6d) To a solution of compound 5d (6 mg, 4 µmol) in MeOH (3 mL) was 
added 10% Pd/C (10 mg). The mixture was stirred overnight under a balloon of H2 at 
room temperature. The reaction mixture was filtered and concentrated under vacuum. 
The residue was dried under vacuum for 1 h upon which the residue was dissolved in 
anhydrous CH2Cl2 (0.5 mL) and freshly distilled TMSBr (0.5 mL) was added at 0 °C 
under argon. The mixture was stirred at room temperature for 1 h followed by removal 
of solvents under vacuum. The resulting residue was then dissolved in MeOH (3 mL) 
and stirred for 1 h followed by removal of solvent to yield 6d (3.3 mg, 100%) as a clear 
oil. 1H NMR (400 MHz, CD3OD) δ 5.24-5.27 (m, 1H), 4.50 (dd, J = 18.4, 6.3 Hz, 1H), 
4.42 (dd, J = 11.9, 4.2 Hz, 1H), 3.95-4.30 (m, 7H), 3.63-3.70 (m, 1H), 2.90-2.97 (m, 2H), 
2.23-2.43 (m, 4H), 1.6-1.74 (m, 6H), 1.30-1.37 (m, 26H), 0.90 (t, J = 6.8 Hz, 3H). 31P 
NMR (CD3OD, 162 MHz) 0.60 (1P), 0.28 (1P), -1.45 (1P). ESMS 846.4 [M+H]+ 
Synthesis of (2R)-1-((6-aminohexanoyl)oxy)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-
2,3,6-trihydroxy-4,5-bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propan-2-
yl tridecanoate (6c) Compound 6c was prepared in a similar manner to compound 6d 
(10 mg, 80%) as a colorless oil from 5c (25 mg, 0.16 mmol). 1H NMR (CD3OD, 400 
MHz) δ 5.23 (m, 1H), 4.48 (dd, J = 18.5, 6.3 Hz, 1H), 4.40 (dd, J = 11.9, 4.2 Hz, 1H), 
4.04-4.28 (m, 6H), 3.97 (dd, J = 9.4, 9.3 Hz, 1H), 3.64 (m, 1H), 2.92 (t, J = 7.3 Hz, 2H), 
2.3-2.42 (m, 4H), 1.54-1.74 (m, 4H), 1.20-1.50 (m, 22H), 0.88 (t, J = 7.1 Hz, 1H); 13C 
NMR (CD3OD, 101 MHz) δ 173.14 (2C), 79.67, 78.49, 77.48, 70.93, 70.03, 69.84 and 
69.76 (1C), 64.68, 61.62, 39.16, 33.56, 32.97, 31.63, 29.34, 29.31, 29.30, 29.18, 29.03, 
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28.99, 28.72, 26.77, 25.39, 24.52, 23.85, 22.28, 12.99; 31P NMR (CD3OD, 162 MHz) δ 
0.64 (1P), 0.32 (1P), -1.33 (1P). ESMS 804.3 [M+H]+ 
Synthesis of (2R)-1-((6-aminohexanoyl)oxy)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-
2,3,6-trihydroxy-4,5-bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propan-2-
yl decanoate (6b) Compound 6b (6.2 mg, 100%) was prepared in a similar manner to 
compound 6d from compound 5b (11 mg, 7 µmol) as a colorless oil. 1H NMR (400 MHz, 
CD3OD) δ 5.20-5.31 (m, 1H), 4.51 (dd, J = 18.5, 6.3 Hz, 1H), 4.43 (dd, J = 11.9, 4.3 Hz, 
1H), 3.90-4.23 (m, 7H), 3.65-3.68 (m, 1H), 2.90-3.00 (m, 2H), 2.28-2.50 (m, 4H), 1.42-
1.74 (m, 6H), 1.25-1.39 (m, 14H), 0.91 (t, J = 6.7 Hz, 3H). 31P NMR (CD3OD, 162 MHz) 
δ 0.75 (1P), 0.40 (1P), -1.16 (1P). ESMS 761.3 [M+H]+ 
Synthesis of (2R)-1-((6-aminohexanoyl)oxy)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-
2,3,6-trihydroxy-4,5-bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propan-2-
yl heptanoate (6a) Compound 6a (1.9 mg, 100%) was prepared in a similar manner to 
compound 6d from compound 5a (3.9 mg, 3 µmol) as a colorless oil. 1H NMR (400 
MHz, CD3OD) δ 5.22-5.31 (m, 1H), 4.47-4.57 (m, 1H), 4.42 (dd, J =18.4, 6.3 1H), 3.8-
4.24 (m, 7H), 2.91-2.96 (m, 1H), 2.35-2.42 (m, 2H), 1.30-1.64 (m, 6H), 1.20-1.29 (m, 
8H), 0.81 (t, J = 6.8 HZ, 3H). 31P NMR (CD3OD, 162 MHz) δ 0.59 (1P), 0.26 (1P), -1.48 
(1P). ESMS 720.2 [M + H]+ 
Synthesis of 4-((6-((2R)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-
bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)-2-(palmitoyloxy)propoxy)-6-
oxohexyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Fl-PIP2-
C15) To a solution of compound 6d (3.3 mg, 4 µmol) in TEAB buffer (0.5 M, 1.8 mL) 
was added a solution of NHS ester 7 (3.7 mg, 8 µmol) in DMF (1.85 mL). The reaction 
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was stirred in the dark at room temperature overnight before the solvents were removed 
under vacuum. Purification via HPLC (BETASIL C18 150 x 10 mm, a gradient starting 
with water and ending with 100% MeOH over 30 min with the flow rate at 5 mL/min) 
yielded PIP2-C15 as a red-orange solid (2.5 mg, 53% from compound 5a). 1H NMR (400 
MHz, CD3OD) δ 6.50-8.56 (m, 9H), 5.14-5.29 (m, 1H), 4.34-4.49 (m, 1H), 4.26-4.29 (m, 
1H), 3.96- 4.26 (m, 6H), 3.62-3.67 (m, 1H), 3.48-3.51 (m, 2H), 2.24-2.41 (m, 4H), 1.49-
1.70 (m, 6H), 1.21-1.34 (m, 26H), 0.90 (t, J = 6.3 Hz, 3H). 31P NMR (CD3OD), 162 MHz) 
δ 2.45 (1P), 1.71 (1P), -0.55 (1P). ESI-HRMS for [M + H]+ calcd 1204.36, found 
1204.3636 
Synthesis of 4-((6-((2R)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-
bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)-2-(tridecanoyloxy)propoxy)-
6-oxohexyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Fl-PIP2-
C12). Fl-PIP2-C12 was synthesized in a similar manner to PIP2-C15 as a red-orange 
solid (55%). 1H NMR (CD3OD, 400 MHz) δ 6.50-8.20 (m, 9H), 5.18-5.24 (m, 1H), 4.30-
4.44 (m, 1H), 4.24 (m, 1H), 3.92-4.18 (m, 6H),  3.61 (m, 1H), 3.34 (m, 2H), 2.22-2.36 
(m, 4H), 1.45-1.65 (m, 6H), 1.14-1.40 (m, 20H), 0.85 (t, J = 7.1 Hz, 3H); 31P NMR 
(CD3OD, 162 MHz) δ 2.43 (1P), 1.70 (1P), -0.54 (1P); ESI-HRMS for [M + H]+ : calcd 
1162.3215, found 1162.3195. 
Synthesis of 4-((6-((2R)-2-(decanoyloxy)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-
trihydroxy-4,5-bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propoxy)-6-
oxohexyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Fl-PIP2-
C9) Fl-PIP2-C9 (2.1 mg, 64%) was prepared from compound 6b (2.6 mg, 3 µmol) in a 
similar manner to PIP2-C15 as a red-orange solid. 1H NMR (400 MHz, CD3OD) δ 6.50-
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8.56 (m, 9H), 5.20-5.28 (m, 1H), 4.43-4.49 (m, 1H), 4.20-4.27 (m, 1H), 3.90-4.20 (m, 
6H) 3.58-3.65 (m 1H), 3.30-3.40 (m, 2H), 2.25-2.36 (m, 4H), 1.30-1.70 (m, 6H), 1.20-
1.30 (m, 14H), 0.84 (t, J = 6.8 Hz, 3H). 31P NMR (CD3OD, 162 MHz) δ 2.79 (1P), 1.92 
(1P), -0.62 (1P). ESI-HRMS for [M + H]+: calcd 1120.27, found 1120.2727 
Synthesis of 4-((6-((2R)-2-(heptanoyloxy)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-
trihydroxy-4,5-bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propoxy)-6-
oxohexyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Fl-PIP2-
C6). Fl-PIP2-C6 (2.0 mg, 67%) was prepared from compound 6a (1.9 mg, 3 µmol) in a 
similar manner to PIP2-C15 as a red-orange solid. 1H NMR (400 MHz, CD3OD) δ 6.40-
8.20 (m, 9H), 5.20-5.24 (m, 1H), 4.31-4.45 (m, 1H), 4.21-4.24 (m, 1H), 3.90-4.27 (m, 
6H), 3.60-3.67 (m, 1H), 3.34-3.40(m, 2H), 2.30-2.40 (m, 4H), 1.35-1.70 (m, 6H), 1.20-
1.36 (m, 8H), 0.89 (t, J = 6.9 Hz, 3H). 31P NMR (CD3OD, 162 MHz) δ 2.72 (1P), 1.83 
(1P), -0.64 (1P). ESI-HRMS for [M + H]+: calcd 1078.22 found 1078.2262 
Synthesis of (2R)-1-((6-(3-(5,5-difluoro-7,9-dimethyl-5H-4ë4,5ë4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)hexanoyl)oxy)-3-
((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-
bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propan-2-yl palmitate 
(BODIPY-PIP2-C15; 10) Boodipy-PIP2-C15 (5.4 mg, 65%)Was prepared from 
compound 6d (7.2 mg, .007 mmol) in similar conditions to Fl-PIP2-C15 1H NMR (400 
MHz, CD3OD) δ 7.43 (s, 1H), 7.01 (d, J = 4.1 Hz, 1H), 6.32 (d, J = 4.0 Hz, 1H), 6.21 (s, 
1H), 5.22-5.27 (m, 1H), 4.50 (q, J = 9.2 Hz, 1H), 4.41 (dd, J = 12.0, 3.6 Hz, 1H), 4.25 – 
3.94 (m, 6H), 3.63 (dd, J = 9.8, 2.7 Hz, 1H), 3.24 – 3.07 (m, 4H), 2.60 (t, J = 7.6 Hz, 
2H), 2.51 (s, 3H), 2.45 – 2.22 (m, 7H), 1.58-1.62 (m, 4H), 1.53 – 1.45 (m, 2H), 1.30-1.25 
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(m 26H), 0.89 (t, J=7.0 Hz, 3H).  31P NMR (162 MHz, CD3OD) δ 0.99, 0.50, -0.87. 
ESMS: 1111.8 [M]+ 
Synthesis of (1S,2S,3R,4S,5S,6S)-2,3,4,5,6-pentakis(methoxymethoxy)cyclohexan-
1-ol (11).  
Compound 11 was synthesized as previously described from myo-inositol [81]. 1H NMR 
(400 MHz, CDCl3) δ 4.92 – 4.76 (m, 6H), 4.76 – 4.70 (m, 4H), 4.08 (t, J = 2.6 Hz, 1H), 
4.00 (d, J = 4.6 Hz, 1H), 3.93 (t, J = 9.7 Hz, 1H), 3.67 (t, J = 9.4 Hz, 1H), 3.50 (dd, J = 
10.1, 2.5 Hz, 1H), 3.47 – 3.39 (m, 15H); 13C NMR (101 MHz, CDCl3) δ 98.67, 98.43, 
97.94, 96.16, 83.07, 79.61, 77.80, 77.31, 77.19, 76.99, 76.67, 76.38, 70.95, 56.35, 
56.28, 56.07, 55.69, 55.66, 28.57. ESMS: 400.2 [M]+ 
Synthesis of (2R)-1-(((benzyloxy)(diisopropylamino)phosphaneyl)oxy)-3-((3-
(((benzyloxy)carbonyl)amino)propanoyl)oxy)propan-2-yl palmitate (12). 
Phosphoramidite 12 (75 mg, 85%) was synthesized from 3d (64 mg, 0.11 mmol) as 
previously described [81]. 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.28 (m, 10H), 5.23-5.16 
(m, 1H), 5.09 (s, 2H), 4.81 – 3.34 (m, 15H), 3.18 (q, J = 6.7 Hz, 2H), 2.29 (t, J = 7.6 Hz, 
4H), 1.61 (d, J = 5.1 Hz, 4H), 1.49 (q, J = 7.5 Hz, 2H), 1.37 – 1.22 (m, 26H), 1.19 – 1.12 
(m, 12H), 0.94 – 0.80 (t, J=6.9 hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.01, 156.34, 
136.61, 128.46, 128.22, 128.04, 127.26, 126.90, 77.31, 76.99, 76.67, 66.55, 65.44, 
65.41, 65.23, 62.61, 61.82, 43.17, 43.06, 42.94, 40.81, 34.30, 33.84, 31.89, 29.67, 
29.63, 29.60, 29.46, 29.33, 29.26, 29.08, 26.15, 24.89, 24.40, 22.66, 14.10. 31P NMR 
(162 MHz, CDCl3) δ 148.79 (0.5 P), 148.64 (0.5P). 
Synthesis of (2R)-1-(((benzyloxy)(((1S,2R,3R,4S,5S,6R)-2,3,4,5,6-
pentakis(methoxymethoxy)cyclohexyl)oxy)phosphoryl)oxy)-3-((3-
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(((benzyloxy)carbonyl)amino)propanoyl)oxy)propan-2-yl palmitate (13)  Compound 
13 (48mg, 70%) was prepared in a similar manner to compound 5d from compound 11 
(30 mg, 0.078 mmol) and phosphoramidite 12 (70 mg, .085 mmol)  as a colorless oil. 1H 
NMR (400 MHz, CDCl3), δ 7.28-7.39 (m, 10H), 5.16-5.22 (m, 1H), 5.07-5.15 (m, 4H), 
4.65-4.88 (M, 10H), 4.26-4.33 (m, 1H), 4.24 (t, J = 2.2 Hz, 1H) 4.06-4.20 (m, 4H), 3.86-
4.00 (m, 2H), 3.32-3.50 (m, 17H), 3.17 (q, J = 6.4 Hz, 2H), 2.24-2.30 (m, 4H), 1.48-1.68 
(m, 8H), 1.25-1.38 (m, 25H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
172.85, 172.80, 172.76, 136.62, 128.72, 128.68, 128.66, 128.48, 128.05, 127.90, 
127.88, 98.80, 98.52, 98.49, 97.48, 96.02, 79.44, 77.32, 77.01, 76.69, 75.68, 74.62, 
69.55, 66.56, 61.59, 56.68, 56.58, 56.53, 56.46, 55.78, 55.63, 40.81, 34.04, 33.70, 
31.90, 29.68, 29.65, 29.63, 29.62, 29.47, 29.34, 29.27, 29.07, 26.13, 24.78, 24.34, 
22.67, 14.10. 31P NMR (162 MHz, CDCl3) δ -1.52 (0.5P), -1.59(0.5P). ESMS: 1087.55 
[M]+ 
Synthesis of (2R)-1-((3-aminopropanoyl)oxy)-3-((hydroxy(((1S,2R,3R,4S,5S,6R)-
2,3,4,5,6-pentahydroxycyclohexyl)oxy)phosphoryl)oxy)propan-2-yl palmitate (14) 
Protected PI intermediate 13 (11 mg, .010 mmol) was de-protected using the same 
conditions previously described for compound 6d yielding compound 11 (6.7 mg, 
quantitative) as a colorless oil. 1H NMR (400 MHz, CD3OD) δ 4.41 (dd, J = 12.0, 4.0 Hz, 
1H), 4.02 (t, J = 9.0 Hz, 1H), 3.78 (t, J = 9.5 Hz, 1H), 3.62 (t, J = 9.5 Hz, 1H), 3.37 (dd, J 
= 12.0, 4 Hz, 1H), 3.18 (t, J=8.0,  1H), 2.93 (t, J = 8.0 Hz, 1H), 2.30-2.40 (m, 4H), 1.39-
1.72 (m, 6H), 1.25-1.36 (m, 26H), 0.89 (t, J = 6.9 Hz, 3H). 31P NMR (162 MHz, CD3OD) 
δ -1.46 (1P). ESMS:644.3 [M+H]+ 
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Synthesis of (2R)-1-((3-(3-(5,5-difluoro-7,9-dimethyl-5H-4ë4,5ë4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)propanoyl)oxy)-3-
((hydroxy(((1S,2R,3R,4S,5S,6R)-2,3,4,5,6-
pentahydroxycyclohexyl)oxy)phosphoryl)oxy)propan-2-yl palmitate (BODIPY-PI-
C15; 15) To a solution of compound 11 (6.7 mg, 9 µmol) in TEAB buffer (0.5 M 160 µL) 
was added a solution of NHS-BODIPY (30 mg/mL 160 µL) in DMF. The reaction was 
stirred in the dark at room temperature before removal of solvents by vacuum. 
Purification by HPLC ( BETASIL C18 150 x 10 mm water-methanol 0-100% over 30 
minutes 5  mL/min)  yielded fluorescent PI-C15 (5.3 mg, 60%) as a deep red solid. 1H 
NMR (400 MHz, CD3OD) δ 7.43 (s, 1H), 7.01 (d, J = 4.0 Hz, 1H), 6.32 (d, J = 4.1 Hz, 
1H), 6.21 (s, 1H), 5.20-5.30 (m, 1H), 4.05-4.25 (m, 5H), 4.44 (dd, J = 12.0, 4 Hz, 1H), 
3.93 (t, J = 8.1 Hz, 1H), 3.77 (t, J = 8.1Hz, 1H), 3.62 (t, J = 8.1 Hz, 1H), 3.37 (dd, J = 
9.7, 2.6 Hz, 1H), 3.10-3.25 (m, 5H),  2.60 (t, J = 8.0 Hz, 1H), 2.51 (s, 3H), 2.29-2.40 (m, 
4H), 2.28 (s, 3H), 1.37-1.65 (m, 6H), 1.29-1.40 (m, 26H),  0.88 (t, J = 7.1 Hz, 3H). 31P 
NMR (CD3OD, 162 MHz) δ 0.17 (1P). ESI-HRMS for [M]+: calcd 847.36, found 847.3586 
Synthesis of 2,5-dioxopyrrolidin-1-yl hept-6-ynoate (16). N-hydroxysuccinimide (100 
mg, .87 mmol) and EDAC-HCl (125 mg, .87mmol) were addeded to a solution of 6-
heptynoic acid (100 mg, 0.79 mmol) in DCM (5 mL) containing 0.5 mL of DMF and 
stirred overnight. To this mixture was added ethyl acetate and the organic layer was 
washed with water and brine. The organic layer was dried over sodium sulfate and then 
concentrated under vacuum. The crude residue was purified by flash chromatography 
(2:1 Hex:EtOAc) to yield pure NHS-ESTer 16 as a waxy solid (140 mg, 80%).1H NMR 
(400 MHz, CDCl3) δ 2.89 – 2.77 (m, 4H), 2.64 (t, J = 7.4 Hz, 2H), 2.24 (td, J = 6.9, 2.7 
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Hz, 2H), 1.96 (t, J = 2.7 Hz, 1H), 1.88 (dt, J = 15.3, 7.4 Hz, 2H), 1.72 – 1.54 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 169.10, 168.31, 83.46, 68.94, 30.40, 27.30, 25.57, 23.51, 
17.95. ESMS: 223.1 [M]+ 
Synthesis of (2R)-1-((6-(hept-6-ynamido)hexanoyl)oxy)-3-
((hydroxy(((1S,2R,3R,4S,5S,6R)-2,3,4,5,6-
pentahydroxycyclohexyl)oxy)phosphoryl)oxy)propan-2-yl palmitate (Alkyne-PI; 
17) 17 (4.5 mg, 78%) was synthesized in a similar manner to PI-C15 from 14 (5 mg, 
.007 mmol) and NHS ester 16 (1.8 mg, 0.008 mmol). 1H NMR (400 MHz, CD3OD) δ 
5.26-5.18 (sm, 1H), 4.45 (dd, J = 11.9, 3.5 Hz, 1H), 4.22 – 4.15 (m, 1H), 4.07 (q, J = 5.1 
Hz, 1H), 3.88 (td, J = 9.0, 8.1, 2.7 Hz, 1H), 3.76 (t, J = 9.5 Hz, 1H), 3.72 – 3.56 (m, 1H), 
2.34 (td, J = 7.4, 1.7 Hz, 4H), 2.24 – 2.14 (m, 6H), 1.74 – 1.68 (m, 2H), 1.66 – 1.55 (m, 
4H), 1.56 – 1.45 (m, 4H), 1.38 – 1.27 (m, 26H), 0.89 (t, J = 6.5 Hz, 4H). 31P NMR (162 
MHz, CD3OD) δ 0.15 (1P). ESMS: 794.4 [M+H]+ 
Synthesis of (S)-16-(4-methoxyphenyl)-3,10-dioxo-1-phenyl-2,11,15-trioxa-4-
azahexadecan-13-yl palmitate (18). A mixture of 2  (350 mg, 0.76 mmol), 1d (234.5 
mg, 0.91 mmol), DCC (189 mg, 0.91 mmol), and DMAP (51 mg, 0.42 mmol) in 
anhydrous CH2Cl2 (6 mL) was stirred at room temperature overnight. The reaction 
mixture was concentrated and purified by flash chromatography (hexane-ethyl acetate = 
2:1) over silica (407 mg, 89%). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.25 (m, 5H), 7.22 
(d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.27 – 5.17 (m, 1H), 5.08 (s, 2H), 4.94 – 
4.82 (m, 1H), 4.52 – 4.39 (m, 2H), 4.33 (dd, J = 11.9, 3.8 Hz, 1H), 4.15 (dd, J = 11.9, 
6.5 Hz, 1H), 3.78 (s, 3H), 3.54 (dd, J = 5.1, 1.4 Hz, 2H), 3.17 (q, J = 6.7 Hz, 2H), 2.35 – 
2.22 (m, 4H) 1.66 – 1.55 (m, 4H), 1.55 – 1.43 (m, 2H), 1.38 – 1.22 (m, 26H), 0.87 (t, J= 
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6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.11, 173.05, 159.29, 156.38, 136.64, 
129.73, 129.28, 128.47, 128.05, 128.03, 113.80, 77.38, 77.06, 76.74, 72.92, 70.00, 
67.87, 66.54, 62.81, 55.33, 55.23, 55.11, 40.81, 34.30, 33.84, 31.91, 29.68, 29.64, 
29.61, 29.58, 29.47, 29.34, 29.27, 29.07, 26.13, 24.94, 24.86, 24.39, 22.67, 14.11. 
ESMS: 720.5 [M+Na]+ 
Synthesis of (S)-1-((6-aminohexanoyl)oxy)-3-((4-methoxybenzyl)oxy)propan-2-yl 
palmitate (19). Protected precursor 18 (7 mg, 0.01 mmol) was dissolved in methanol (7 
mL). Pyridine (1 uL) and Pd/C (10 mol %) were added to the mixture. The mixture was 
stirred under a balloon of hydrogen gas for 30 minutes followed by filtration of the metal 
catalyst through celite. The filtrate was collected and concentrated under vacuum to 
yield free amine. The free amine was used directly in the next reaction with no further 
purification (5. 4 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 8.6 Hz, 2H), 6.87 
(d, J = 8.6 Hz, 2H), 5.21 (ddd, J = 5.3, 3.4, 1.4 Hz, 1H), 4.46 (d, J = 6.6 Hz, 2H), 4.32 
(dd, J = 11.8, 3.9 Hz, 1H), 4.15 (dd, J = 11.8, 6.4 Hz, 1H), 3.80 (s, 3H), 3.55 (dd, J = 
5.0, 1.1 Hz, 2H), 3.06 – 2.86 (m, 2H), 2.37 – 2.20 (m, 4H), 1.69 – 1.51 (m, 4H), 1.50 – 
1.36 (m, 2H), 1.34 – 1.16 (m, 26H), 0.87 (t, J=6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 173.16, 172.90, 159.28, 129.75, 129.29, 113.80, 77.32, 77.00, 76.68, 72.94, 69.99, 
67.92, 62.91, 55.26, 39.67, 34.31, 33.53, 31.91, 29.69, 29.66, 29.64, 29.63, 29.49, 
29.35, 29.28, 29.09, 27.27, 25.84, 24.94, 24.00, 22.68, 14.11. ESMS: 564.4 [M+H]+ 
Synthesis of (S)-1-((6-(3-(5,5-difluoro-7,9-dimethyl-5H-4ë4,5ë4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)propanamido)hexanoyl)oxy)-3-((4-
methoxybenzyl)oxy)propan-2-yl palmitate (20). Free amine 19 (5 mg, 0.009 mmol) 
was dissolved in anhydrous DMF (150 µL) followed by the addition of 5 µL TEA. After 
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spinning for 10 minutes under argon, BODIPY-NHS (5.2 mg, 0.013 mmoL) in 200 µL of 
DMF was added slowly. The reaction proceeded overnight in the dark followed by 
concentration under a stream of nitrogen. The crude mixture was then purified on silica 
gel (2:1 EtOAc:Hex, Rf ~0.45) to yield protected fluorescent intermediate (5.6 mg, 76%) 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.18 (m, 2H), 7.09 (s, 1H), 6.91 – 6.81 (m, 3H), 
6.29 (d, J = 4.0 Hz, 1H), 6.12 (s, 1H), 5.70-5.75 (m, 1H), 5.30–5.16 (m, 1H), 4.45 (d, J = 
6.8 Hz, 2H), 4.32 (dd, J = 11.9, 3.8 Hz, 1H), 4.15 (dd, J = 11.9, 6.5 Hz, 1H), 3.80 (s, 
3H), 3.54 (d, J = 5.1, 1.2 Hz, 2H), 3.26 (t, J = 7.5 Hz, 2H), 3.23 – 3.11 (m, 2H), 2.62 (t, J 
= 7.4 Hz, 2H), 2.56 (s, 3H), 2.35 – 2.18 (m, 7H), 1.67 – 1.56 (m, 4H), 1.46 – 1.35 (m, 
2H), 1.34-1.22 (m, 26H), 0.87 (t, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.14, 
173.10, 171.57, 168.98, 167.79, 159.28, 129.73, 129.28, 128.28, 127.85, 124.01, 
123.78, 120.72, 120.39, 117.56, 116.75, 113.79, 72.93, 70.00, 67.89, 62.80, 55.25, 
39.19, 36.00, 34.31, 33.84, 31.91, 30.32, 29.68, 29.65, 29.62, 29.48, 29.34, 29.28, 
29.11, 29.08, 26.21, 25.57, 24.94, 24.43, 23.35, 22.67, 14.91, 14.18, 14.11, 11.31, 
11.29. ESMS: 838.8 [M+H]+ 
Synthesis of (S)-1-((6-(3-(5,5-difluoro-7,9-dimethyl-5H-4ë4,5ë4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)propanamido)hexanoyl)oxy)-3-hydroxypropan-2-yl 
palmitate (Boidpy-DAG; 21) Protected intermediate 20 (6 mg, 0.007 mmol) was 
dissolved in DCM (10 mL) containing 5% water followed by the addition of DDQ (3.5 
mg, 0.015 mmol). The reaction proceeded for 4 hours and was monitored by TLC (2:1 
EtOAc:Hex, Rf ~0.25) for completion.  DCM (25 mL) were then added and the reaction 
mixture was washed with 10% NaHCO3 and brine. The mixture was then purified by 
column chromatography(10% Methanol in Chloroform) to yield pure fluorescent DAG 
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(3.3 mg, 65%).1H NMR (400 MHz, CDCl3) δ 7.10 (s, 1H), 6.89 (d, J = 4.1 Hz, 1H), 6.30 
(d, J = 4.1 Hz, 1H), 6.12 (s, 1H), 5.85-5.79 (m, 1H), 5.05–5.05 (m, 1H), 4.30 (dd, J = 
11.8, 4.6 Hz, 1H), 4.20 (dt, J = 11.7, 5.8 Hz, 1H), 3.75 – 3.63 (m, 2H), 3.29 – 3.14 (m, 
4H), 2.62 (t, J = 7.4 Hz, 2H), 2.56 (s, 3H), 2.39 – 2.24 (m, 7H), 1.67 – 1.56 (m, 4H), 1.46 
– 1.35 (m, 2H), 1.34-1.22 (m, 26H), 0.87 (t, J = 6.9Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 173.40, 173.38, 171.71, 128.34, 123.81, 120.40, 117.60, 77.31, 76.99, 76.67, 71.95, 
61.95, 61.32, 39.14, 39.05, 36.06, 34.26, 33.89, 31.91, 29.68, 29.67, 29.64, 29.60, 
29.46, 29.35, 29.25, 29.09, 29.08, 29.01, 26.14, 26.11, 24.91, 24.50, 22.68, 14.92, 
14.11, 11.30. ESMS: 717.4 [M+H]+ 
Synthesis of (R)-1-((6-(((benzyloxy)carbonyl)amino)hexanoyl)oxy)-3-
((bis(benzyloxy)phosphoryl)oxy)propan-2-yl palmitate (22). To a solution of 
tetrazole (12 mg, 0.045 mmol) in anhydrous DCM (2 mL) was added dibenzyl N,N-
diisoproyl phosphoramidite (25 µL, 0.045 mmol) under argon followed by the addition of 
free hydroxyl C15 lipid 3d (24 mg, 0.041 mmol) in 0.5 mL of anhydrous DCM. The 
reaction stirred overnight and was then cooled to -40*C followed by the addition of 
ditertbuyyl peroxide (15 µL of 5.5 M solution) and the mixture was allowed to slowly 
warm to room temperature. The crude mixture was then purified via flash 
chromatography (1:1 Hex:EtOAc, Rf ~0.35) to yield pure protected intermediate (13 mg, 
75%).  
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.27 (m, 15H), 5.22 – 5.13 (m, 1H), 5.09 (s, 2H), 
5.05 – 5.00 (m, 4H), 4.97 – 4.91 (m, 1H), 4.25 (dd, J = 11.9, 4.4 Hz, 1H), 4.12 – 4.03 
(m, 3H), 3.22 – 3.12 (m, 2H), 2.34 – 2.17 (m, 4H), 1.67 – 1.44 (m, 6H), 1.38 – 1.20 (m, 
26H), 0.87 (t, J = 6.9 Hz 3H).13C NMR (101 MHz, CDCl3) δ 172.84, 172.78, 156.38, 
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136.63, 135.59, 135.57, 135.52, 128.61, 128.58, 128.46, 128.06, 128.02, 127.93, 
127.91, 127.84, 127.81, 77.32, 77.20, 77.00, 76.68, 69.50, 69.45, 69.26, 69.18, 66.53, 
65.34, 65.28, 61.62, 40.80, 34.07, 33.90, 33.72, 31.89, 29.67, 29.66, 29.63, 29.60, 
29.57, 29.45, 29.33, 29.24, 29.07, 29.04, 26.11, 24.77, 24.72, 24.35, 24.28, 22.66, 
14.10. 31P NMR (162 MHz, CDCl3) δ -1.04 (1P). ESMS: 839.0 [M+H]+ 
Synthesis of (R)-1-((6-aminohexanoyl)oxy)-3-(phosphonooxy)propan-2-yl 
palmitate (23). Protected intermediate 22 (18 mg, 0.021 mmol) was dissolved in ethyl 
acetate (8 mL) and Pd/C (10 mol %, 5 mg) was added. The mixture was stirred 
overnight under a balloon of hydrogen gas and the catalyst was filtered via celite and 
washed with 1:1 chloroform:methanol. The fully deprotected intermediate was used 
directly in the next reaction without further purification (10 mg, 96%). 
1H NMR (400 MHz, CDCl3) δ 5.23 – 5.12 (m, 1H), 4.34 – 4.17 (m, 2H), 4.05 – 3.93 (m, 
2H), 2.95 (s, 2H), 2.45 – 2.35 (m, 3H), 2.35 – 2.27 (m, 2H), 1.74 – 1.55 (m, 4H), 1.51 – 
1.40 (m, 2H), 1.34-1.18 (m, 26H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
206.95, 173.12, 172.88, 77.31, 76.99, 76.67, 69.69, 62.66, 61.46, 39.70, 34.12, 33.59, 
31.91, 30.91, 29.71, 29.68, 29.66, 29.64, 29.60, 29.54, 29.46, 29.36, 29.27, 29.17, 
29.11, 26.84, 25.46, 24.83, 24.78, 24.26, 22.68, 21.03, 14.10. 31P NMR (162 MHz, 
CDCl3) δ 0.37 (1P). ESMS: 524.7 [M+H]+ 
Synthesis of (R)-1-((6-(3-(5,5-difluoro-7,9-dimethyl-5H-4ë4,5ë4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)propanamido)hexanoyl)oxy)-3-(phosphonooxy)propan-2-
yl palmitate (BODIPY-PA; 24) Free amine 23 (10 mg, .019 mmol) was dissolved in 
DMF (150 µL) and 100 µL of TEAB buffer (0.5 M) were added followed by an addition 
10 µL of chloroform to fully solubilize the compound. After spinning for 10 min, BODIPY-
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NHS was added in 150 µL of DMF. The reaction was stirred for 1 hour and checked for 
completion by TLC (0.1% AcOH in 65:35:4 CHCl3:MeOH:H2O) followed by 
concentration under vacuum. The crude mixture was purified on silica gel (65:35:4 
CHCl3:MeOH:H2O Rf- 0.5) to yield pure fluorescent PA (7.5 mg, 50%). 1H NMR (400 
MHz, CDCl3 δ 7.09 (s, 1H), 6.87 (d, J = 4.0 Hz, 1H), 6.27 (d, J = 4.0 Hz, 1H), 6.10 (s, 
1H), 5.25 – 5.12 (m, 1H), 4.33 (dd, J = 11.9, 3.8 Hz, 1H), 4.14 (dd, J = 11.9, 6.0 Hz, 
1H), 3.99 (t, J = 6.0 Hz, 2H) 3.24 (t, J = 7.4 Hz, 2H), 3.16 (d, J = 6.2 Hz, 2H), 2.61 (t, J = 
7.4 Hz, 2H), 2.54 (s, 3H), 2.38-2.18 (m, 7H), 1.59 – 1.50 (m, 6H), 1.47 – 1.34 (m, 2H), 
1.31 – 1.15 (m, 26H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 207.05, 
177.24, 143.83, 128.31, 123.78, 84.62, 77.31, 76.99, 76.67, 39.24, 35.73, 34.23, 33.82, 
31.91, 30.91, 29.72, 29.68, 29.66, 29.35, 29.19, 29.09, 24.85, 24.33, 22.67, 21.45, 
14.87, 14.10, 11.27. 31P NMR (162 MHz, CDCl3) δ 2.12 (1P). ESMS: 798.7 [M+H]+ 
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CHAPTER 3. CELLULAR DELIVERY OF SYNTHETIC PIP REPORTERS		
3.1	Introduction	
 
 With fluorescent reporters BODIPY-DAG-C15, BODIPY-PIP2-C15, BODIPY-
PtdIns-C15 in hand we sought to investigate various methods of cellular delivery of 
these reporters. Because of the negative resting potential of the plasma membrane it is 
difficult to achieve the delivery of a negatively charged substrate [39]. Further 
complicating delivery is the presence of a solvation shell of water molecules around the 
hydroxyl groups in the head group of PIP reporters, which makes delivery through the 
hydrophobic core of the membrane also a challenge [92, 93]. A large problem in 
achieving systematic analysis of PIPs is the difficulty and unreliability of current delivery 
methods of synthetic PIP reporters [20, 93]. A carrier:cargo method utilizing charge-
charge interaction with histones is the most frequently cited for PIP delivery. Pipette 
perfusion and microinjection are other methods that have been used though we sought 
only to explore passive methods of delivery [62, 87, 94]. Unfortunately, these methods 
have a number of drawbacks that may not make them effective for a systematic 
approach to studying PIP metabolism. The concentration of synthetic PIP2 used in this 
method are 4-10 times the concentration of endogenous substrate at 40 and 100 µM, 
which can greatly alter the pool of PIPs [87, 94]. Because the concentration and ratio of 
PIPs drive biological processes, such a perturbation of the pathway can result in 
unwanted pathway activation. Indeed, a large calcium flux is seen in this method as well 
as reporters exclusively metabolized to DAG due to the activation of intrinsic signaling 
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pathways making this method highly unsuitable when attempting to discern the roles of 
multiple metabolites within the pathway [87, 94] To effectively measure PIP metabolism 
using fluorescent reporter technology, a simple and non-intrusive cellular delivery 
method is required [87, 95]. Such a delivery method must definitively show the delivery 
of a reporter that is therein capable of metabolism via multiple enzymes.  Photocaging 
methods have also been described for synthetic lipid reporters, including PIPs, and are 
an excellent method for analysis as it gives temporal control over release of the 
substrate[92, 93, 96-99]. Various caged, 
non fluorescent, PIPs have been 
synthesized and delivered to cells including 
PIP3 and PI(3)P as wells IP3 and have 
indeed been useful tools in dissecting 
specific locations of PIP biology[92, 93, 96, 
99]. In the method, the phosphate esters 
are ‘caged’ with a photocleavable group, 
often coumarin or nitrobenzyl, which allows 
for passive diffusion into the cell (Figure 
3.1 A). The caging groups can then be released by rapid exposure to UV light releasing 
the active metabolite [92, 93, 96-99]. These tools often contain a bioactivatable 
protecting group used for masking of hydrophilic groups on lipid reporters, such as the 
hydroxyls of PIPs to reduce the energy penalty of entering the hydrophobic region of the 
lipid bilayer [92, 93, 99] (Figure 3.1B).  These groups are cleaved over time via 
nonspecific esterases within the cell leaving only the photo cleavable group to be 
A.	
	B.	
	
Figure 3.1 Common Chemical 
Moieties in Photocaging of 
Phospholipids: A. Structures of 
common photocaging moieties B. 
Structures of bioactivateable 
protecting groups. 
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removed. Various caged, non-fluorescent, PIPs have been synthesized and delivered to 
cells including and have indeed been useful tools in dissecting PIP biology [92, 93, 96, 
99]. For instance, caged PI(3)P was successful in inducing endosomal fusion following 
uncaging [92]. Likewise, various caged tri-functional lipid probes of DAG and 
sphingosine have been developed and has proven to be a powerful technology for the 
temporal release of active metabolite [98]. A major drawback of this approach the 
synthesis of such lipids is a long and arduous process. Further utility of this system to 
systematically analyze PIP metabolism has yet to be examined as previous studies 
focused on biological outcomes or proteomics and not metabolite identification [92, 93, 
98, 99].  
 Another system that has proven effective99 at the delivery of a variety of cargo is 
the use of cationic lipids, seen in Figure 3.2, to formulate various liposomes capable of 
cellular entry [100, 101]. When mixed with negatively charged cargo, such as DNA or 
other cargo, lipid complexes have shown significant efficacy in cellular transfection and 
subsequent protein expression[100, 102-105].  Cationic liposomes have also proven 
effective at delivery of cytotoxic agents such as chemotherapy drugs in clinical 
applications [100, 101, 106]. Because of the effectiveness of cationic liposomes for 
cellular delivery of various charged substrates, and their composition made up of 
amphiphilic lipids similar to our reporters, it is plausible that a cationic liposome could be 
formulated to include a fluorescent PIP reporter for use in delivery and cellular analysis.  
 Another class of liposomes with fusogenic properties composed of 1,2-
dioleoylphosphatidylethanolamine (DOPE) and 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), shown in Figure 3.2B, have also been shown to be effective at 
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delivery of charged substrates including mRNA and intracellular proteins. In this 
method, the liposome fuses with the plasma membrane instead of entering the cell via 
endocytosis, which can lead to lysosomal degradation of the cargo [107]. Further, this 
method has been previously reported to be capable of delivering phospholipids tagged 
with fluorophores for membrane visualization via fluorescence microscopy [84, 108]. 
Interestingly, the addition of the delocalized π electron system of the fluorophores 
appeared to have a beneficial effect to the efficacy of membrane fusion of the liposome, 
with BODIPY being on of the most effective [84, 107, 108]. While fusogenic liposomes 
have been reported to contain fluorescent lipids for visualization the utility of such a 
system to systematically analyze PIP metabolism has yet to be determined.   
 
A.		
	B.	
	
Figure 3.2 Common lipids used in Liposome Formulation for 
Cellular Transfection: A. Cationic lipids commons found in 
combination with neutral ‘helper lipids’ to achieve a cationic liposome 
for cellular transfection. B. Common lipids in fusogenic liposome 
formulations  
	59	
 In this chapter, we describe our attempts at cellular delivery of fluorescent 
BODIPY-DAG-C15, BODIPY-PtdIns-C15 and BODIPY-PIP2-C15 reporters, as well as 
a model phospholipid to explore a variety of delivery options. We detail our attempts at 
previously described delivery methods, liposome delivery, intra-molecular charge 
masking, photocaging, and unique carrier-cargo complexes for use in cellular PIP 
analysis.  
3.2 Results and Discussion 
3.2.1 Delivery of BODIPY-DAG-C15, BODIPY-PIP2-C15, and model phospholipid 36 
to Cells 
 To investigate the effects of charge on the delivery of fluorescent PIP 
metabolites, we first compared the effectiveness of delivering the neutral BODIPY-
DAG-C15 and BODIPY-PIP2-C15 without the use of a carrier system. HEK293AD cells 
were incubated with 1 µM BODIPY-DAG-C15 or BODIPY-C15-PIP2 and cells were then 
analyzed via fluorescence microscopy after 15 min of incubation with the probe. As 
expected, and consistent with literature precedent, fluorescent DAG is efficiently taken 
up by the cells as indicated by the increase in fluorescent signal whereas no fluorescent 
PIP2 is present in the cell [21, 61, 109]. This confirmed that indeed charge was a factor 
for the delivery of PIP reporters, though the difference in structures with PIP2 containing 
multiple phosphates on the inositol head group could also have played a part in the 
delivery efficiency. 
 To further confirm that charge was a major factor in delivery, a model 
phospholipid 36 was synthesized that more closely resembles DAG and PA to further 
test this theory and for comparison to other delivery techniques. The development of the 
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model phospholipid allows for the exploration and comparison of multiple novel delivery 
methods due to easier synthesis compared to inositol containing PIP derivatives. The 
compound contains a phosphate group to examine the effect of charge and a 
fluorophore for detection. The synthetic route is shown in Scheme 3.1. Compound 32 
was synthesized via reduction over Ra-Ni/ H2 of azide intermediate synthesized as 
previously reported [110].  Next, the amine was coupled N-Boc caproic acid with 
coupling reagent DCC and DMAP followed by Cbz deprotection via hydrogenolysis over 
Pd/C to yield compound 33. Heptanoic acid was coupled to the free amine again using 
DCC and DMAP to give compound 34. The silyl ether was removed via hydrogen 
fluoride in pyridine to yield a free alcohol, which was subsequently phosphorylated via 
phosphoramidite coupling resulting in fully protected intermediate 35. Deprotection of 
the amino-Boc group was achieved via HCl in dioxane followed by final deprotection of 
the Benzyl protecting groups again via hydrogenolysis over Pd/C. Finally, the free 
amine was tagged with BODIPY fluorophore using 9 in basic conditions as previously 
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described to yield fluorescent model compound 36.
 
When 1 µM of compound 36 was incubated with HEK293-AD cells no increase in 
cellular fluorescence after 15 min was observed as seen in Figure 3.3, again indicating 
the presence of a negative charge is the largest obstacle to overcome in cellular 
delivery and neutralization of the charge may deem our reporters suitable for cellular 
delivery. 
	
Scheme 3.1 Synthesis of Fluorescent Model Phospholipid 36. 
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3.2.2 Photocaging for the Delivery of Model Phospholipid 36 
 In our lab, we have developed a general, one-step method to enable 
phospholipids cell permeable and photoactivatable, MKS-1, shown in Figure 3.4A, 
which reduces the need for complex synthesis to achieve a caged phospholipid and 
instead could be applied directly to our suite of PIP reporters [111]. 
Trimethylsilyldiazomethane (TMS) has been shown to selectively alkylate phosphoric 
acid under mild conditions. By replacing the methyl group with photocleavable 
nitrobenzyl yields a useful tool for the general caging of free phosphates using 
compound MKS-1. Compound 36 was easily caged using MKS-1 in MeOH yielding 
	
	
Figure 3.3 Carrier Free Delivery of Fluorescent Lipid Reporters HEK293AD 
cells (0.5 million) in growth medium (DMEM with 10% FBS, 2 mL) were plated into 
a 35 mm dish and were grown in an incubator at 37 C with 5% CO2. After 24 h, 
the cells were treated with 1 µM of the indicated fluorescent compound. Cells 
were visualized with a confocal microscope 15 minutes after incubation. 
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compound 54 and could be effectively uncaged back to compound 36 following 
treatment with light between 300-400 nm in wavelength as shown in Figure 3.4B [111].  
 
 
 
With the caged 54 in hand, we tested whether caging the phosphoric acid 36 was 
sufficient to make it cell-permeable in HEK293-AD cells. Cells were treated with either 1 
µM of uncaged 36 or caged 54 and the cellular fluorescence was examined 15 min after 
A.	
	
B.	
	
	
Figure 3.4 Generation and Uncaging of Compound 54 
with MKS-1: A. Structure of photocaging reagent MKS-1. 
B. Caging of phospholipid 36 with MKS-1 generated 54 
which could be uncaged following treatment with UV light.  
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compound treatment. As shown in figure 3.5, strong fluorescence that was primarily in 
cytosol was detected for caged 54-treated cells. In contrast, no fluorescence signals 
were detected in cells treated with uncaged 36. These results clearly demonstrated that 
caging the phosphate group in 54 was sufficient to make it cell-permeable and thereby 
validated our approach of neutralizing charge for the delivery of phospholipids [111]. 
 
3.2.3 Histone Delivery of PIPs 
 Despite the previously described drawbacks of using histones as a delivery 
method, we used this carrier-cargo method as a starting point to analyze the 
effectiveness of cellular delivery of fluorescent PIPs with this carrier system in our 
hands with a lower concentration of fluorescent reporter to avoid activation if intrinsic 
	
Figure 3.5 Delivery of Uncaged 36 and Caged 54 to Cells: HEK293AD 
cells (0.5 million) in growth medium (DMEM with 10% FBS, 2 mL) were 
plated into a 35 mm dish and were grown in an incubator at 37 C with 5% 
CO2. After 24 h, the cells were treated with 1 µM of 36 or 54. Cells were 
visualized with a confocal microscope 15 minutes after incubation. 
	
	65	
signaling pathways. BODIPY-PtdIns-C15 1 µM were mixed with histones and incubated 
with 293AD cells. Cells were then washed with PBS and analyzed for increase in 
fluorescence via fluorescence microscopy after 30 minutes of incubation. A BODIPY-
tagged QS-11, which is known to be cell permeable, was used as a control [112, 113]. 
Despite literature reports, we were unable to achieve efficient delivery of fluorescent 
PIPs as seen in Figure 3.6, leading our efforts to focus on new and alternative delivery 
methods of fluorescent PIPs  
 
 
3.2.4 Cationic Liposomes for the Delivery of PIPs 
 Because of the effectiveness of cationic liposomes for cellular delivery of various 
charged substrates, we sought to examine the capability of applying this technology to 
PIP delivery.  Cationic liposomes were formulated using 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (EDMPC), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (EDPPC), 
1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (EDOPC), N,N-Dimethyltetradecylamine 
(di-C14 DAB), and 1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP) according 
	
Figure 3.6: Histone Delivery of BODIPY-PtdIns-C15 to Cells 
HEK293AD cells (0.5 million) in growth medium (DMEM with 10% FBS, 2 
mL) were plated into a 35 mm dish and were grown in an incubator at 37 
C with 5% CO2. After 24 h, the cells were treated with 1 µM of 
histone:BODIPY-PtdIns-C15 or BODIPY-QS11. Cells were visualized 
with a confocal microscope 15 minutes after incubation. 
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to previous formulations proven effective at delivery of GFP plasmids were formulated 
include BODIPY-PtdIns-C15 according to Table 3.1 [105]. HEK293AD cells were 
incubated with liposomes to contain a final BODIPY-PtdIns-C15 of 1 µM. Cellular 
fluorescence was examined 15 minutes after incubation. While 2 of the 3 formulations 
showed an increase in cellular fluorescence as seen in Figure 3.7 cell morphology 
indicated that the method was toxic to cells. Due to the toxicity of cationic liposomes 
with BODIPY-PtdIns-C15, new mechanisms of liposomal delivery were explored.  
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3.2.5 Fusogenic Liposomes for the Delivery of PIPs 
 Because of the broad range of applications of fusogenic liposomes and effective 
labeling of the plasma membrane in various cell lines with the addition of fluorescently 
tagged lipids, we sought to apply this method for the delivery of fluorescent BODIPY-
PtdIns-C15. Effective labeling of the plasma membrane would present the lipid in the 
correct cellular location to be metabolized as well as avoid potentially detrimental 
endosome uptake and lysosome degradation [102]. Liposomes with known fusogenic 
Table	3.1	Cationic	Liposome	Formulations	for	BODIPY-
PIP2-C15	Cellular	Delivery	 	
	
Formulation	(molar	ratio)18	
1	
EDMPC:EDPPC:BODIPY-PtdIns-C15	
(25:75:10)	
2	
EDOPC:diC14DAB:	BODIPY-PtdIns-C15	
(30:70:10)	
3	
EDOPC:DMTAP:	BODIPY-PtdIns-C15	
(60:40:10)	
	
	
Figure 3.7 Cationic Liposome Delivery of BODIPY-PtdIns-C15 to 
Cells: HEK293AD cells (0.5 million) in growth medium (DMEM with 10% 
FBS, 2 mL) were plated into a 35 mm dish and were grown in an incubator 
at 37 C with 5% CO2. After 24 h, the cells were treated with a cationic 
liposomes according to Table 3.1 for a final BODIPY-PtdIns-C15 
concentration of 1 µM. Cells were viewed with a confocal microscope 
following 15 minutes of incubation. 
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properties were formulated according to Table 3.2 to include DOPE, DOTAP, and 
BODIPY-PtdIns-C15 [84, 107, 108]. 
 Liposomes were prepared by the lipid film method; briefly the lipids dissolved in 
chloroform were mixed in the desired ratios following by removal of solvent under a 
stream of N2 and then dried under vacuum for 1 hour. Lipids were then resuspended in 
25 mM HEPES (pH 7.4) for a lipid concentration of 2 mg/mL. HEK293-AD cells were 
treated with liposomes for a final concentration of BODIPY-PtdIns-C15 of 1 µM and the 
cellular fluorescence was examined following 15 minutes of incubation. As seen in 
Figure 3.8, an increase in cellular fluorescence was observed for the liposomes and 
moreover the liposomes did not result in cellular toxicity as was the case previously 
using cationic liposome formulations. 
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 Next, we sought to do a preliminary evaluation of reporter stability/lipid 
metabolites to see if the method would be amenable to systematic metabolic analysis. 
We would expect to see a large concentration of BODIPY-PtdIns-C15 with possible 
metabolites that could be compared with previously synthesized standards. Cell pellets 
were harvested and lipid contents were extracted via Folch extraction with acidic 
chloroform:methanol mixture and analyzed for the fluorescent lipid contents by TLC and 
Table	3.2	Fusogenic	Liposome	Formulations	for	BODIPY-PIP2-C15	
Cellular	Delivery	 	 	 	 	 	 	 	
	
Formulation	(Mass	Ratio)[20-22]	
4	 DOPE:DOTAP:BODIPY-PtdIns-C15		(1:1:0.2)	
5	 DOPE:DOTAP:BODIPY-PtdIns-C15		(1:1:0.1)	
6	 DOPE:DOTAP:DIR:BODIPY-PtdIns-C15I		(1:1:0.1:0.2)		
	
Figure 3.8 Fusogenic Liposome Delivery of BODIPY-PtdIns-C15 to 
Cells. Fig Figure 3.7 Cationic Liposome Delivery of BODIPY-
PtdIns-C15 to Cells.  HEK293AD cells (0.5 million) in growth medium 
(DMEM with 10% FBS, 2 mL) were plated into a 35 mm dish and were 
grown in an incubator at 37 C with 5% CO2. After 24 h, the cells were 
treated with fusogenic liposomes formulated according to Table 3.2 
(2mg/mL final concentration) with a final BODIPY-PtdIns-C15 
concentration of 1 µM. Cells were viewed with a confocal microscope 
following 15 minutes of incubation. 	
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CE [62, 65, 71, 76]. The CE analysis was carried out by Dr. Angela Proctor in Dr. Nancy 
Allbritton’s lab.  Unfortunately, very little intact BODIPY-PtdIns-C15 was observed, with 
~70% of the reporter converted to fluorescent DAG for each sample as seen in a 
representative CE trace and quantification in Figure 3.9. An unknown metabolite was 
also generated that was unable to be identified with available standards. It is unknown 
whether this was through PIP family of enzymes or non-specific cleavage occurring in 
the endosome/lysosome as the punctate structure of the fluorescence indicates this as 
the most likely mode of entry.  
 
The breakdown of the reporter lead to this method to be abandoned for a non-liposomal 
based mode as delivery. Overall, it does not appear liposomes are an effective method 
to use for the quantification of cellular PIP metabolites, most likely due to endosomal 
uptake of the liposome [100, 103, 105]. 
	
Figure 3.9 CE Analysis of Metabolites Generated using Fusogenic 
Liposome Delivery of BODIPY-PtdIns-C15. HEK293AD Cells were treated 
with fusogenic liposomes as described in Figure 3.8 followed by lipid 
extraction after 15 minutes of incubation. Lipids were resuspended in 
propanol and analyzed by CE-LIF using synthesized fluorescent for peak 
identification. 
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3.2.6 Intramolecular Charge Masking Strategy with Guanidine for the Delivery of 
Phospholipids 
 A unique and recently widely used cellular transfection is the use of guanidine 
rich molecular transporters on a variety of scaffolds[114]. Since the discovery that the 
HIV Tat protein was capable of crossing the cell membrane which is facilitated by the 9-
mer Tat49-57 (RKKRRQRRR) there has been increased interest in the mechanism of cell 
penetration by this peptide [115, 116]. When the 9-mer was modified to contain lysines 
instead of arginines, the efficacy of the cell penetrating peptide (CPP) dropped 
remarkably indicating that it was not simply the cationic charge carried by either of the 
residues[114, 117, 118]. This can be attributed to the ability of forming a bidentite 
hydrogen bond assisted ion pair with phosphate groups shown in Figure 3.10. When 
the hydrogen bond assisted interaction is removed by replacing the hydrogen atoms on 
the terminal guanidine amino groups with methyl groups, the cell penetrating properties 
of the peptide are lost further indicating the interaction is a vital part of cell penetration 
versus that of just charge [119].  
 
 
	
Fig. 3.10 Bidentite Interaction 
Between Guanidine and 
Phosphates. Hydrogen bond assisted 
ion pair between guanidine and 
phosphate groups resulting in a net 
neutral charge. 
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 Since this discovery of guanidine promoting cell-penetration, guanidinium rich 
CPPs have been used for cellular transfection of various cargoes including small 
molecules, peptides, proteins, and oligonucleotides both non-cavalently and covalently 
attached to the cargoes[114, 120, 121]. Various non-peptidic scaffolds such as 
glycosides, dendrmers, and carbohydrates have also been modified to contain 
guanidine moieties and have retained cell-penetrating functions again showing the 
power of guanidine to induce cellular uptake [95, 114, 117, 120, 122, 123].  Various 
modes of cellular uptake have been proposed including adaptive translocation where 
charge-neutralization moves the cargo through the membrane as well as induction of 
endocytosis because blocking of endocytosis does not fully negate cell-penetrating 
capability [114, 120].  
 Based on the success of an intermolecular carrier-cargo system with guanidine 
scaffolds, and the variety of modes of cellular uptake, we examined if inclusion of a 
guandine moiety could allow for the cellular delivery of phospholipids. We explored an 
intramolecular phosphate masking strategy via a derivative of compound 36 by the 
addition of a guanidne group at the terminal end of the alkyl chain to generate 
compound 53 with the hopes of neutralizing the negative charge. We hypothesized that 
an intramolecular interaction would induce charge neutralization via proximity while also 
allowing for the guanidine to interact with the cell membrane and allow for cell-
penetration. When applied to a fluorescent PIP reporter, such a technology would 
provide a simple and effective strategy for reporter delivery that does not require the 
use of multiple reagents and/or chemical manipulation of the reporters.  
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 Guanidine containing model phospholipid compound 53 was synthesized 
according to Scheme 3.2. Azide 31 was synthesized according to literature protocol 
followed by reduction via H2/Rainey Ni to yield primary amine 32 [110].  Fmoc-caproic 
acid was then coupled via DCC and catalytic DMAP coupling to yield compound 46. To 
generate compound 48, the Cbz group was cleaved via hydrogenolysis in methanol 
followed by DCC/DMAP coupling of guanidine caproic acid 47, which was synthesized 
according to literature protocol [124]. The silyl ether was removed via hydrogen fluoride 
in pyridine to yield a free alcohol 49, which was subsequently phosphorylated via 
phosphoramidite coupling as previously described resulting in intermediate 50. 
Cleavage of the Cbz as well as Bn deprotection of the phosphate group via 
hydrogenolyisis yielded intermediate 51 which was then tagged with the flourophore 
BODIPY using reagent 9 as described previously to yield fluorescent intermediate 52. 
Finally, Boc deprotection of the guanidine was achieved with HCl in dioxane to yield 
final guanidine containing phospholipid compound 53. 
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 With guanidine containing compound 53 in hand, we tested whether 
intramolecular masking of the phosphonic acid would render the compound cell 
permeable when compared to the cell uptake of compound 36. HEK-293AD cells were 
incubated with 1 µM of compound 36 or compound 53 and cellular fluorescence was 
examined following 15 min of incubation. Unfortunately, the presence of a guanidine 
group did not increase cellular uptake of the model phospholipid as there was no 
discernable fluorescence increase for compound 36, as previously described, and no 
fluorescence increase seen following treatment with compound 53. Because of these 
	
	
Scheme 3.2: Synthesis of Intramolecular Charge Masking Model 
Compound 53 
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findings, this guanidine approach was not applied to PIP reporters and lead us to 
explore a novel carrier:cargo system that utilized polyamines and guanidine moieties. 
3.2.7 Charge Altering Releasable Transporters (CARTs) for the Delivery of PIPs 
 A recent development in cellular delivery is the synthesized charge altering 
releasable transporters (CARTs) shown in Figure 3.11 [96, 114, 125-127]. These 
transporters have been synthesized to contain both lipid units that contribute to required 
hydrophobicity for membrane interaction, which we have seen in the case of 
photocaging equally as important as neutralizing charge, as well as various cationic 
moieties to interact with polyanionic cargo and the negatively charged membrane. 
Interestingly, guanidine is a popular cationic moiety included in CARTs, again verifying 
our attempt at using guanidines previously in delivery [117, 125-127].  
  This technology is attractive because the oligomers can be ‘tuned’ using 
different monomers and degrees of polymerization for increased interaction with a 
specific cargo. In this method, polyanionic cargo is mixed in a 1:1 molar ration with a 
CART to form a protective and CART-cargo complex that neutralizes the negatively 
charged cargo. This complex is then delivered to the cell via hydrophobic interaction 
and charg-charge interaction with the membrane where the cargo is released via 
hydrolysis of the CART releasing a neutral non-toxic small molecule and the polyanionic 
cargo to the cytosol[117, 125-127].   
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Because of the stability of the cargo in complex with CARTs, they have been effective at 
the delivery of a wide range of cargos including small molecules, metals, imaging 
agents, siRNA and even proteins to both a variety of cell lines and animal models. 
D13:A11 (A11) was effective at EGFP mRNA delivery across a panel of cell lines with 
greater than 90% transfection efficiency in all cell lines, whereas lipofectamine achieved 
only 20-60% efficiency and results varied greatly amongst cell lines [125]. Likewise, A11 
was effective at delivery of EGFP mRNA in mice making this a viable delivery vector for 
both c experiments in both cell culture and animal models,, and could potentially be 
used in therapeutic applications [125].  Guanidinium rich transporter D7:G7 (G7) was 
effective at the delivery of polyanionic myo-inositol derivative 5-diphospho-myo-inositol 
pentakisphosphate (InsP7) [96]. Further, this structure contains guanidine groups that 
have been previously described as promising for delivery.  Because of the similarity in 
the core structure to IP3, it is probable, that this technology could be utilized to deliver 
other polyanionic inositol containing molecules. Therefore, we examined the ability of 
CARTs to deliver BODIPY-PIP2-C15 because of the polyanionic state of the inositol 
head group. HeLa cells were incubated with CART:PIP2 complex with a final BODIPY-
PIP2-C15 concentration of 500 nM and cellular fluorescence was examined 2 hours 
	
Figure 3.11 CARTs for the Delivery of BODIPY-PIP2-C15: Structure of 
CARTs previously shown efficacious for the delivery of plasmids and inositol 
phosphates examined for their transfection capability of fluorescent PIP2 
reporters [108, 116-118]. 
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after incubation. As shown in Fig 3.12, CART:PIP2 complexes resulted in a strong 
increase in cellular fluorescence compared to cells treated only with BODIPY-PIP2-C15 
indicating delivery is indeed a result of the addition of the CART and charge 
neutralization. 
 
We next examined the basal metabolic profile produced from the CART delivery. Again 
HEK293-AD cells were incubated with CART:BODIPY-PIP2-C15 (500 nM PIP2) and cell 
pellets were collected following 30 minutes and 2 hours incubation. A Folch lipid 
extraction was performed to obtain all lipid metabolites followed by concentration of the 
bottom lipid layer under a stream of N2. Lipid films were then resuspended in 1:1 
chloroform:methanol for TLC analysis.  As seen in Figure 3.13, both CARTs were 
successful in achieving cellular delivery, with the G7 CART delivering a larger amount of 
PIP2 over 30 minutes than that of A7, with time dependent increase in cellular 
	
Figure 3.12 Delivery of BODIPY-PIP2-C15 to Cells via CART systems 
A11 and G7. HeLa cells were incubated with PIP2:CART complexes for 2 
hours in serum free media. Cells were washed 2X with media and 
analyzed via confocal microscopy. Both G7 and A11 showed significant 
fluorescence increase with no fluorescence increase without the use of a 
transporter. Experiment performed by Dr. Collin McKinlay. 
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fluorescence. Synthesized standards BODIPY-DAG-15, BODIPY-PtdIns-C15, and 
BODIPY-PIP2-C15 were used to identify new metabolic products produced in the 
experiment as well as confirm the presence of delivered PIP2 reporter. A large amount 
of intact BODIPY-C15-PIP2 was still present in the sample after 2 hours, a result that 
had yet to be achieved in the lab previously or with any other delivery method. Likewise, 
only small amounts of DAG were produced compared liposomal delivery. Following 2-
hours of incubation, a strong BODIPY-PtdIns-C15 signal begins to appear as well as a 
small amount of BODIPY-PIP2-C15 though the regioisomer of PIP cannot be 
distinguished by TLC.  
 
	
	
Figure 3.13 TLC analysis of Fluorescent Metabolites Generated from 
BODIPY-PIP2-C15 in Cells using the CART System. HEK293-AD cells 
were treated with 500 nM of BODIPY-PIP2-C15:CART complexes for the 
indicated time points followed by lipid extraction. Lipids were suspended 
in 1:1 chloroform:methanol and analyzed by TLC  and fluorescent 
scanning. 
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3.3 Conclusions and Future Directions 
 We have examined a plethora of delivery techniques for the cellular delivery of 
fluorescent PIP reporters. Consistent with literature protocol, fluorescent DAG freely 
enters the cells. In contrast negatively charged PIP2 and compound 36 are not cell 
permeable. In our attempts at histone delivery, we were unable to achieve cellular 
delivery with this method in multiple experiments. Likewise, literature reports of this 
method and analysis of metabolite generation look similar to our studies with fusogenic 
liposomes with DAG being the most abundant metabolite. Because of the inability to 
easily reproduce this method, as well as a metabolic profile that does not match the 
cellular distribution of lipids, this method is not effective for the systematic analysis of 
PIPs. 
 Direct neutralization of the negative charge, via covalent photocaging methods 
using MKS-1 greatly increased the delivery of caged 54 compared to 36. However, 
preliminary examinations of caging BODIPY-PtdIns-C15 or BODIPY-PIP2-C15, not 
described in this thesis, was not effective in delivering reporters to cells. Due to the 
presence of bioactivatebale hydrophobic moieties, such as butonyl, used in previous 
reports of photocaged PIPs it is likely we must increase the hydrophobic properties of 
MKS-1. Another potential problem for the photocaging of PIP2 with MKS-1 is the 
creation of a dipohosphate ester, which is chemically unstable and can induce 
phosphate migration to neighboring hydroxyls. A possible change to the structure would 
be the introduction of a guanidine moiety or other cationic amine. This would create full 
charge neutralization with only the addition of a single photocaging group to each 
phosphate thus eliminating problems of stability. This could also increase delivery by 
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interacting directly with the membrane and result in a higher release efficiency because 
of the presence of fewer photo-cleavable groups. 
 Both cationic liposomes and fusogenic liposomes are not applicable to 
systematic analysis of PIPs. Cationic liposomes caused a high level of cell toxicity with 
suboptimal delivery as seen by fluorescence microscopy. This is more likely due to the 
entry mechanism or cellular perturbation by the liposome more so than BODIPY-PtdIns-
C15 because of the low level of cellular delivery. Similarly, fusogenic liposomes showed 
low level of cellular delivery in punctate structures most likely to be endosomes. While 
the cells remained healthy, analysis of the metabolites revealed that in a short amount 
of time the reporter had been metabolized to DAG and an unknown metabolite. It is 
unknown if this is a result of nonspecific cleavage in the endosome or enzymatic 
turnover, however this profile does not represent the endogenous distribution of 
metabolites and is not applicable for use in biological studies. 
 Despite the widespread use of scaffolds containing guanidine for cellular 
delivery, our intramolcular charge masking strategy was ineffective at achieving cellular 
delivery of compound 53. This, however, does not rule out future application of this 
design. It is possible that the alkyl chain containing the guanidine is not long enough to 
interact directly. Therefore future compounds should be synthesized altering the chain 
length and examining any changes in cellular delivery potential. This could also 
underscore the importance of the ratio between charge masking and hydrophobicity. It 
is possible that without intramolecular interaction, the reporter could enter via adaptive 
translocation through interaction with the guanidine and the membrane phospholipids 
and an increase in hydrophobicity may stimulate these effects.  
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 . The most successful and promising delivery method was the use of CARTs in 
a carrier-cargo complex with BODIPY-PIP2-C15. Both A11 and G7 were able to achieve 
significant delivery the fluorescent PIP2, though the time dependent increase between 
the 2 carts was different suggesting a more efficient escape for the reporter using CART 
G7. G7 also contains a guanidine moiety consistent with the hypothesis of guanidine 
containing compounds being effective at PIP delivery. Incubation with only 500 nM final 
concentration of fluorescent PIP2 is far less than used in previous reporters of PIP2 
delivery while still providing enough reporter to visualize via fluorescence microscopy 
and for extraction to use for TLC and CE analysis [87, 94]. Further, extractions and 
analysis of lipid metabolites showed a distribution of metabolites consistent with 
endogenous substrates [39, 128]. Because of the consistency with previously reported 
distribution, we will begin to use this method for examining cellular distribution of 
metabolites in cancer cell lines in response to various stimuli and pharmacological 
agents. Further optimization of experimental parameters such as incubation time will 
need to be explored in a variety of cell lines as HEK293AD cells yielded different 
transfection efficiencies between A11 and G7. This will ensure that loading and cellular 
concentration of reporter will be a factor in the experimental results. Overall this method 
is the most promising one in hand for use in systematic PIP cellular analysis, which will 
be detailed in chapter 4 of this dissertation. 
3.4 Experimental 
All reagents were obtained from commercial sources and were used without further 
purification. Thin layer chromatography was per- formed on 250 µm silica plates and 
column chromatographic purifica- tions were performed on 200–300 mesh silica gel. 1H 
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NMR and 13C NMR spectra were recorded at 400 MHz and 100 MHz, respectively. 
Chemical shifts (δ) are reported in parts per million (ppm) with residual solvent 
resonances as references.  
MKS-1 and caged compound 54 were synthesized by Dr. Manish K. Singh 
Dr. Colin McKinlay and Dr. Paul Wender from Stanford University generously provided 
all CARTs (A11 anf G7). 
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3.4.1 Confocal Microscopy HEK293AD cells (0.5 million) in growth medium (DMEM 
with 10% FBS, 2 mL) were plated into a 35 mm dish and were grown in an incubator at 
37 °C with 5% CO2. After 24 h, the cells were treated with fluorescent reporter (1 µM). 
Cells were washed 2X with DMEM and visualized with a confocal microscope. 
3.4.2 Preparation of Cationic Liposomes Cationic lipids and BODIPY-PtdIns-C15 in 
chloroform (10 mg/mL) were mixed to their desired molar ratios (Table 3.1) followed by 
removal of solvent under a stream of N2 and drying for 1 hour. The lipid film was 
resuspended in 25 mM HEPES buffer to give a final lipid concentration of 2 mM with 
200 µM BODIPY-PtdIns-C15 followed by sonication for 10 minutes. Liposome mixtures 
were then incubated with cells for  a final BODIPY-PtdIns-C15 concentration of 1 µM 
3.4.3 Preparation of Fusogenic Liposomes Lipids and BODIPY-PtdIns-C15 in 
chloroform (10 mg/mL) were mixed according to Table 3.2 for a final lipid concentration 
of 2 mg/mL with 200 µM BODIPY-PtdIns-C15 followed by removal of solvent under a 
stream of N2 and drying for 1 hour. The lipid film was resuspended in 25 mM HEPES 
buffer followed by sonication for 10 minutes. Liposome mixtures were then incubated 
with cells for a final BODIPY-PtdIns-C15 concentration of 1 µM. 
3.4.4 Extraction of Lipid Metabolites 
150 uL of 40:20:1 (v:v:v) CHCl3:Methanol:HCl was added to the cell pellet and left at 
room temperature for 10 minutes. 50 uL of CHCl3 and 50 uL of water were added and 
the mixture vortexed heavily for 3 minutes. The mixture was then centrifuged at 4*C at 
3200 RPM for 8 minutes resulting in phase separation. The bottom layer was collected, 
dried under a stream of N2 and resuspended in 30 uL of 1:1 CHCl3:MeOH (v:v) for TLC 
analysis.  
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3.4.5 TLC analysis of Lipid Metabolites 
TLC plates (Merck, Silica Gel-60) were pre-treated with a solution of 1.2% potassium 
oxalate and 1.2 mM EGTA in MeOH/water (v:v = 2:3) and heated at 110 °C for 20 min 
before use. Lipid films were diluted in CHCl3/ MeOH (v:v = 1:1) and spotted on a TLC 
plate directly. The TLC plate was then developed in CHCl3:Acetone:MeOH:AcOH:water 
(v:v:v:v:v = 80:30:26:24:14) and scanned on a Typhoon 9400 Variable Mode Imager 
(lex/lem = 488 nm/520 nm). The fluorescence intensity of various spots on the TLC 
plate was quantified with ImageQuant software (V.5.0). 
3.4.6 CE Analysis of Lipid Analytes 
Capillary electrophoresis coupled with laser induced fluorescence detection (CE-LIF, 
488 nm excitation) was performed on a custom-built system mounted to the stage of an 
inverted microscope, described previously in detail[75]. Fused silica capillaries were 38 
cm long with a 20.5 cm effective length [30 µm inner diameter and 360 µm outer 
diameter (Polymicro Technologies; Phoenix, AZ)] and were conditioned prior to use by 
rinsing for 1 h in DI H2O, 12 h in 0.1 M NaOH, 1 h in DI H2O, 6 h in 0.1 M HCl, and 12 h 
in DI H2O. Prior to each run, capillaries were rinsed with 1 M NaOH and DI H2O for 5 
min each and with electrophoretic buffer for 10 min by application of pressure to the 
capillary outlet. Buffer at the capillary inlet and outlet was completely refreshed prior to 
each electrophoretic run. The composition of the electrophoretic buffer was 80 mM 
NaH2PO4, pH 6.8 containing 15% 2-propanol and a field strength of 210 V cm-1 was 
used for all separations. Internal standards and samples were hydrodynamically loaded 
by raising the inlet 3 cm relative to the outlet and holding the capillary inlet in the sample 
for 10 sec. The inlet was then lowered to the height of the outlet and electrophoresis 
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was initiated by application of a negative voltage to the outlet while grounding the inlet. 
Electropherograms were plotted and analyzed utilizing OriginLab 9.0 (OriginLab 
Corporation; Northampton, MA). 
3.4.7 Chemical Synthesis 
Synthesis of Benzyl (R)-(1-amino-3-((tert-butyldimethylsilyl)oxy)propan-2-
yl)carbamate (32): To a solution of azide 31 (synthesized as previously described 
[110]) (620 mg, 1.7 mmol) in ethyl acetate (25 mL) was added a slurry of Rainey Ni. The 
reaction proceeded under a balloon of H2 at room temperature for 3 h and was then 
filtered through celite. The filtrate was concentrated to afford amine 7 that was used 
directly without further purification (540 mg, 94%). 1H NMR (400 MHz, CDCl3) δ 7.24-
7.33 (m, 5H), 5.33 (br. s, 1H), 5.08 (s, 2H), 3.60-3.70 (m, 3H), 2.82 (br. s, 2H), 1.95 (br. 
s, 2H), 0.80 (s, 9H), 0.02 (s, 6H). 13C NMR (CDCl3, 100.5 MHz) δ 156.44, 136.62, 
128.58, 128.42, 128.16, 128.02, 77.36, 66.76, 63.12, 54.19, 42.81, 25.92, 25.82, 18.29, 
18.11 -3.42, -5.44. LC-MS Calcd [M+H] 339.20; found 339.2 
 
Synthesis of Tert-butyl (R)-(6-((2-amino-3-((tert-
butyldimethylsilyl)oxy)propyl)amino)-6-oxohexyl)carbamate (33): To a solution of 
32 (250 mg, 0.74 mmol) in CH2Cl2 (15 mL) was added N-Boc caproic acid (205 mg, 
0.87 mmol) followed by the addition of DCC (182 mg, 0.87 mmol) and DMAP (18 mg, 
0.15 mmol). The reaction proceeded at room temperature for 4 h followed by removal of 
solvent and subsequent addition of EtOAc.  The mixture was filtered and the filtrate 
concentrated under vacuum. The resulting residue was purified by column 
chromatography (67% EtOAc in hexane) to yield protected intermediate (345 mg, 85%). 
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The fully protected intermediate (150 mg, 0.27 mmol) was dissolved in methanol 
followed by the addition of 10 mol% Pd/C and the reaction proceeded overnight at room 
temperature under a balloon of hydrogen. The catalyst was filtered over celite, the 
filtrate was concentrated and and the resulting residue was purified by flash 
chromatography (10% MeOH in CH2Cl2) over silica gel to yield pure free amine 8 (105 
mg, 93%). 1H NMR (400 MHz, CD3OD) δ 3.64 (dd, J = 10.1, 4.8 Hz, 1H), 3.54 (dd, J = 
10.1, 5.9 Hz, 1H), 3.34 – 3.26 (m, 2H), 3.14 (dd, J = 13.5, 7.0 Hz, 1H), 3.04 (t, J = 7.0 
Hz, 2H), 2.99 – 2.89 (m, 1H), 2.22 (t, J = 7.5 Hz, 2H), 1.71 – 1.58 (m, 2H), 1.45-140 (m, 
12H), 1.41 – 1.29 (m, 3H), 0.94 (s, 9H), 0.11 (s, 6H). 13C NMR (CD3OD, 100.52 MHz) δ 
176.50, 158.51,79.76, 66.32, 65.85, 61.99, 57.65, 53.69, 49.85, 43.28, 41.17, 37.01, 
34.76, 30.66, 28.81, 27.48, 26.65, 26.39,19.15, -5.32. LC-MS Calcd [M+H] 418.30; 
found 418.3 
 
Synthesis of tert-butyl (R)-(6-((3-((tert-butyldimethylsilyl)oxy)-2-
heptanamidopropyl)amino)-6-oxohexyl)carbamate (34):To a solution of free amine 
33 (120 mg, 0.29 mmol) and heptanoic acid (41 mg, 0.32 mmol) in CH2Cl2 (10 mL) was 
added DCC (65 mg, 0.32 mmol) and DMAP (7 mg, 0.06 mmol). The reaction proceeded 
at room temperature for 4 h followed by removal of solvent and subsequent addition of 
EtOAc.  The mixture was filtered and the filtrate concentrated under vacuum. The 
residue was then purified by flash chromatography (67% EtOAc in hexane) over silica 
gel to yield  compound 9 (122 mg, 89%). 1H NMR (400 MHz, CD3OD) δ 4.02 – 3.90 (m, 
1H), 3.73 – 3.54 (m, 2H), 3.36 – 3.25 (m, 4H), 3.00 (t, J = 7.0 Hz, 2H), 2.26 – 2.11 (m, 
3H), 1.57 (dt, J = 12.2, 7.4 Hz, 3H), 1.68 – 1.25 (m, 19H), 1.47 – 1.39 (m, 13H), 1.31 (q, 
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J = 7.0, 5.1 Hz, 6H), 0.99 – 0.88 (m, 12H), 0.06 (s, 6H).13C NMR (CD3OD, 100.5 MHz) δ 
176.62, 176.34, 64.18, 52.79, 49.85, 41.24, 41.18, 37.35, 37.04, 32.74, 30.68, 30.02, 
28.80, 27.47, 27.03, 26.71, 26.38, 26.20, 23.59, 19.16, 14.41, -5.29, -5.33 . LC-MS 
Calcd [M+H] 530.39; found 530.4 
Synthesis of Tert-butyl (R)-(6-((3-((bis(benzyloxy)phosphoryl)oxy)-2-
heptanamidopropyl)amino)-6-oxohexyl)carbamate (35): Silated intermediate 34 (67 
mg, .13 mmol) in THF (3.0 mL) was added commercial 30% HF in pyridine (250 uL). 
The reaction proceeded for 2.5 hours at room temperature followed by the addition of 
saturated sodium bicarbonate and extracted into EtOac. The organic layer was 
collected, dried under Na2SO4 and concentrated under vacuum. The crude residue was 
purified by flash chromatography (5% MeOH in CH2Cl2) over silica gel to afford a free 
hydroxyl intermediate (48 mg, 89%). The free hydroxyl (48 mg, .12 mmol) was added to 
a solution of tetrazole (64 mg, .24 mmol) and commercial dibenzyl N,N-
Diisopropylphosphoramidite (83 mg, .24 mmol) in anhydrous CH2Cl2 (4 mL) under 
Argon gas. The mixture stirred for 18 hours and was then cooled to -40° C followed by 
the addition of 5.5 M TBUOOH (85 uL). The mixture was allowed to warm to room 
temperature slowly followed by removal of solvents and the residue purified by flash 
chromotagraphy (5% MeOH in CH2Cl2) over silica to afford pure phosphorylated 
compound 10 (60 mg, 75%) 1H NMR (400 MHz, CD3OD) 7.31-7.36 (m, 10H), 5.06 (s, 2 
H), 5.04 (s, 2H) 4.15-4.21 (m, 1H), 3.96-4.06 (m, 2H), 3.80-3.89 (m, 1H), 3.22-3.44 (m, 
4H), 2.98-3.5 (m, 2H), 2.09-2.20 (m, 4H), 1.44-1.68 (m, 6H), 1.40-1.43 (m, 9H), 1.20-
1.39 (m, 6H), 0.88 (t, J = 8 Hz, 3H). 13C NMR (CD3OD, 100.5 MHz) δ176.60, 176.35, 
129.78, 129.70, 129.25, 128.18, 128.55, 128.43, 105.62, 105.27, 70.96, 70.91, 68.32, 
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68.27,68.21, 68.14, 68.00, 62.76, 50.78, 50.75, 50.70, 50.47, 41.17, 40.47, 37.20, 
37.02, 36.94, 36.71, 33.18, 32.72, 32.69, 30.65, 30.00, 29.95, 28.80, 27.46, 27.00, 
26.88, 26.66, 26.60, 23.58, 23.56, 14.42. 31P NMR (CD3OD, 162 MHz) δ -1.38 (1P). LC-
MS Calcd [M+H] 676.36; found 676.3 
 
Synthesis of (R)-3-(6-(3-(5,5-difluoro-7,9-dimethyl-5H-4ë4,5ë4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)propanamido)hexanamido)-2-heptanamidopropyl 
dihydrogen phosphate (36): Fully protected intermediate 34 (20 mg, 0.03 mmol) was 
dissolved in dioxane (2 mL) and added 4M HCl (500 uL). The reaction was monitored 
for completion by TLC (10% MeOH in CH2Cl2) for 3 h followed by removal of solvent 
under vacuum. The so-formed HCl salt (18 mg, 0.03 mmol) was dissolved in methanol 
(10 mL) followed by the addition of 10 mol% Pd/C and stirred overnight under a balloon 
of hydrogen at room temperature. The mixture was filtered through celite and filtrate 
concentrated under vacuum to yield fully deprotected free amine intermediate which 
was used directly in the next reaction. To the free amine (3.6 mg, 0.008 mmol) in 0.5 M 
TEAB buffer (150 uL) was added NHS-BODIPY (4.7 mg, 0.016 mmol) in DMF (150 uL). 
The mixture stirred overnight in the dark followed by removal of solvent under a stream 
of nitrogen gas. The crude reaction mixture was purified via HPLC  (30-80% 0.1% TFA 
in MeOH over 60 min) to yield pure fluorescent compound 11 (3.6 mg, 46% combined 
from compound 10). 1H NMR (400 MHz, CD3OD) δ 7.44 (s, 1H), 7.02 (d, J = 4.0 Hz, 
1H), 6.33 (d, J = 4.1 Hz, 1H), 6.22 (s, 1H), 4.18 (s, 1H), 4.03 – 3.91 (m, 2H), 3.44 – 3.35 
(m, 2H), 3.25 – 3.12 (m, 4H), 2.60 (t, J = 7.6 Hz, 2H), 2.52 (s, 3H), 2.29 (s, 3H), 2.23 – 
2.15 (m, 4H), 1.55 – 1.40 (m, 6H), 1.38-1.25 (m, 6H), 0.90 (t, J=7.9 Hz, 3H).13C NMR 
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(CD3OD, 100.5 MHz) δ176.49, 176.18, 174.53, 129.66, 125.78, 121.30, 117.74, 111.44, 
50.75, 50.66, 49.85, 49.50, 49.28, 49.07, 47.82, 40.98, 40.29, 37.27, 37.05, 36.02, 
32.75, 30.09, 30.06, 27.60, 26.96, 26.64, 25.67, 23.60, 14.41, 11.19, 9.31; 31P NMR 
(CD3OD, 162 MHz) δ 0.02 (1P) ESMS 670.30 [M+H]+ 
Synthesis of (9H-fluoren-9-yl)methyl (R)-(6-((2-(((benzyloxy)carbonyl)amino)-3-
((tert-butyldimethylsilyl)oxy)propyl)amino)-6-oxohexyl)carbamate (46): To Fmoc-
Caproic Acid (350 mg, 0.99 mmol) was added DCC (205 mg, 0.99 mmol), catalytic 
DMAP (23 mg, 0.19 mmol), and anhydrous DCM. The mixture was spun for 30 min 
followed by the addition of free amine (320 mg, 0.94 mmol) in DCM. The reaction 
proceeded for 4 hours followed by removal of solvent under vacuum. The mixture was 
then suspended in ethyl acetate and filtered followed by column chromatography (2:1 
EtOac:Hex) to afford pure product (541 mg, 85%). 1H NMR (400 MHz, CDCl3) 1H NMR 
(400 MHz, CDCl3) δ 7.74 (d, J = 7.6, 2H), 7.58 (d, J = 7.6 2H), 7.47 – 7.30 (m, 6H), 6.18 
– 5.97 (m, 1H), 5.44 – 5.27 (m, 1H), 5.07 (s, 2H), 4.88 (s, 1H), 4.37 (d, J = 7.0 Hz, 2H), 
4.22 – 4.16 (m, 1H), 3.84 – 3.73 (m, 1H), 3.71 – 3.54 (m, 2H), 3.48 – 3.37 (m, 1H), 3.21 
– 3.09 (m, 2H), 1.63 – 1.23 (m, 6H), 0.87 (s, 9H) ,0.04 (s, 6H).13C NMR (CDCl3, 100.52 
MHz)  δ 173.74,156.92, 156.58, 144.14, 141.34, 136.49, 128.65, 128.29, 128.17, 
127.76 127.14, 125.18, 120.07, 77.36, 66.95, 66.62, 63.80, 52.66, 49.94, 49.24, 47.43, 
42.23, 41.70, 40.91, 36.49, 34.09, 29.83, 29.73, 26.36, 25.98, 25.81, 25.75, 25.22, 
25.08,18.35, 0.13 -5.38, -5.41 ESMS: 674.74[M+H]+ 
Synthesis of (Z)-6-(2,3-bis(tert-butoxycarbonyl)guanidino)hexanoic acid (47): To a 
solution of N-Caproic acid in MeOH at 0*C was added TEA slowly followed by addition 
of commercial diboc-trifyl-guanidine. The reaction proceeded overnight and was 
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monitored for disappearance of starting material (2:1 Hex: EtOAc). EtOAc was added 
and the mixture was then washed with 2M Sodium Bisphosphate. The organic layer was 
dried over Sat. sodium sulfate followed by column chromatography to afford pure N-
guanidinyl caproic acid (95%). 1H NMR (400 MHz, CD3OD) δ 3.34 (t, J = 7.1 Hz, 2H), 
2.29 (t, J = 7.4 Hz, 2H), 1.72 – 1.54 (m, 4H), 1.50 (s, 9H), 1.45 (s, 9H), 1.40 – 1.35 (m, 
2H). 13C NMR (101 MHz, CD3OD) δ 177.50, 164.55, 157.58, 154.23, 84.45, 80.36, 
49.85, 49.64, 49.50, 49.43, 49.28, 49.21, 49.07, 49.00, 48.79, 48.57, 48.36, 41.64, 
34.84, 29.86, 28.57, 28.22, 27.39, 25.72.ESMS: 174.3 [M+H-Boc]+ 
Synthesis of 48: To a solution of CBz amine (200 mg, 0.130mmol) in methanol was 
added Pd/C (5 mol %). The reaction proceeded under a balloon of hydrogen for and 
monitored ever 30 minutes by TLC (10% MeOH in DCM) until completion to avoid the 
slower Fmoc deprotection. Following filtration and vacuum concentration, flash 
chromatography (10% MeOH in DCM) yielded pure amine as a colorless oil (135 mg, 
85%). The free amine (80 mg, 0.15 mmol) was added immediately following addition of 
anhydrous DCM at 0*C to a solution of N-Guanidine Caproic Acid (85 mg, 0.22 mmol), 
DCC (45 mg, 0.22 mmol), and DMAP (3.8 mg, 0.03 mmol) The reaction proceeded for 
4hr until the starting material was consumed. The reaction proceeded at RT for 2hr until 
starting material was consumed whereas solvent was evaporated EtOAc was added 
and solid filtered followed by column chromatography (5% MeOH in DCM) to afford pure 
material as a colorless oil (110mg, 84%).1H NMR (400 MHz, CDCl3) 1H NMR (400 
MHz, CDCl3) δ 11.77 – 11.18 (m, 1H), 8.31 (d, J = 6.8 Hz, 1H), 7.76 (d, J = 6.8 Hz, 2H), 
7.68 – 7.55 (m, 2H), 7.47 – 7.30 (m, 4H), 6.38 – 6.15 (m, 2H), 4.47 – 4.33 (m, 2H), 4.05 
– 3.93 (m, 1H), 3.80 – 3.67 (m, 1H), 3.50 – 3.33 (m, 5H), 3.24 – 3.13 (m, 2H), 2.28 – 
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2.12 (m, 4H), 1.45-1.52 (m, 24H), 1.49 (s, 7H), 1.36 (s, 6H), 0.90 (s, 9H), 0.07 (s, 
6H).13C NMR (CDCl3, 100.52 MHz)  δ 174.17, 173.82, 156.63, 156.26,153.47, 144.17, 
141.45,127.79, 127.16, 125.21, 120.09, 110.17, 83.24, 79.42, 77.36, 68.13, 66.65, 
63.35, 51.51, 47.47, 40.90, 36.66, 36.58, 29.80, 28.95, 28.47, 28.23, 28.18, 26.63, 
26.44, 26.02, 25.41, 25.34, 18.38, 0.15, -5.26, -5.36. ESMS: 894.5 [M]+ 
Synthesis of 49: A solution of protected hydroxyl (100 mg, 0.11 mmol) in THF (3.4 mL) 
was added commercial 30% HF in pyridine (300 uL). The reaction was monitored to 
completion by TLC (10% MeOH in DCM) and after 2.5 hrs  saturated sodium 
bicarbonate was added followed by extraction into EtoAc. The organic layer was dried 
over saturated NaSO4 followed by column purification (10% MeOH in DCM) to afford 
pure hydroxyl as a colorless oil (74 mg, 85%). 1H NMR (400 MHz, CDCl3) δ 11.54-11.45 
(m, 1H), 8.34 – 8.29 (m, 1H), 7.76 (d,  J=7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2H), 7.44-7.29 
(m, 4H), 6.37 (d, J = 7.6 Hz, 1H), 6.25 (s, 1H), 5.08 – 4.84 (m, 1H), 4.40 (d, J = 6.9 Hz, 
2H), 4.21 (t, J = 6.7 Hz, 1H), 3.86 (s, 1H), 3.74 – 3.57 (m, 1H), 3.50 (d, J = 10.6 Hz, 2H), 
3.38 (q, J = 6.3 Hz, 2H), 3.32 – 3.14 (m, 3H), 2.25 – 2.17 (m, 4H), 1.52-1.55 (m, 4H) 
1.32-1.59 (M, 30H).13C NMR (CDCl3, 100.52 MHz) δ 173.48, 169.65, 169.08, 
163.70,156.28, 153.47, 144.11, 127.83, 127.18, 125.15, 120.13, 83.27, 79.46, 77.36, 
66.70, 61.82, 51.58 47.44, 40.88, 39.71, 36.50, 36.32, 31.09, 29.76, 28.85, 28.85, 
28.23, 26.48, 26.26, 25.40, 25.17, 0.15 ESMS: 781.4 [M+H]+ 
Synthesis of 50: To a solution of tetrazole (44 mg, .167 mmol) and hydroxyl (65 mg, 
.08 mmol) in anhydrous DCM was added drop-wise commercial Dibenzyl N,N-
Diisopropylphosphoramidite (56 uL, .166 mmol). Reaction was monitored by TLC (5% 
MeOH in DCM) and after 24 hr. the mixture was cooled to -40*C followe
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addition of 5.5M TBUOOH (60 uL) . The reaction mixture was warmed slowly, 
concentrated, and purified via column chromatography (5% MeOH in DCM) to afford 
pure product (65 mg, 75%)1H NMR (400 MHz, CD3OD) δ 7.76 (d, J = 7.5 Hz, 2H), 7.61 
(d, J = 7.5 Hz, 2H), 7.40 – 7.21 (m, 14H), 5.03 (dd, J = 8.4, 1.7 Hz, 4H), 4.30 (d, J = 6.9 
Hz, 2H), 4.26 – 4.11 (m, 2H), 4.11 – 3.91 (m, 2H), 3.39 – 3.21 (m, 4H), 3.08 (t, J = 6.9 
Hz, 2H), 2.29 – 2.01 (m, 4H), 1.71 – 1.53 (m, 4H), 1.45-1.48 (m, 24H) 1.35 – 1.23 (m, 
6H).13C NMR (CD3OD, 100.52 MHz) δ 176.52, 176.02, 164.14, 158.78, 157.29, 
154.12, 145.31, 144.38, 142.54, 137.06, 137.04, 136.99, 136.98, 129.76, 129.69, 
129.22, 129.16, 129.15, 128.74, 128.51, 128.40, 128.11, 126.15, 120.91, 111.37 84.50, 
80.54, 70.93, 70.88, 68.28, 68.23, 67.53, 50.76, 50.68, 48.46, 41.70, 41.54,  40.48, 
36.92, 30.54, 29.74, 28.58, 28.22, 27.34, 26.53, 26.47. 31P NMR (CD3OD, 162 MHz) δ 
0.15 (1P) 
Synthesis of 52: To a solution of benzyl and Fmoc protected intermediate 50 (12 mg, 
0.011 mmol) in methanol was added 5 mol% Pd/C. The reaction was stirred overnight 
under a balloon of hydrogen gas. Following filtration of catalyst free phosphate ester 
and free amine was achieved in quantitative yield 7.35 mg, 0.011 mmol) as a colorless 
oil 51. To 51 (5 mg, .008 mmol) in 0.5M TEAB buffer was added NHS-Fluorophore in 
DMF in a total reaction volume of 300 uL. The mixture stirred overnight in the dark 
followed by removal of solvent under a stream of nitrogen gas. The crude mixture was 
purified by HPLC (30-80% 0.1% TFA in Methanol over 30 minutes product elutes at 43 
minutes) to yield Boc-protected fluorogenic compound (55% 3.8 mg). 1H NMR (400 
MHz, CD3OD) δ 7.44 (s, 1H), 7.02 (d, J= 4.0 Hz, 1H), 6.32 (d, J= 4.0Hz, 1H), 6.22 (s 
1H), 4.15-4.22 (m, 1H), 3.81-4.02 (m, 2H), 3.45-3.55 (m, 2H), 3.35-3.40 (m, 2 H), 3.14-
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3.22 (m, 4H), 2.61 (t, J= 7.6 Hz, 2H), 2.52 (s, 3H), 2.29 (s, 3H), 2.18-2.27 (m, 4H),1.30-
1.72 (m, 30H). 31P NMR (CD3OD, 162 MHz δ -.06 (1P). ESMS: 913.5 [M+H]+ ; 713.5 [M-
BOC+H]+ 
Synthesis of guanindine containing model system 53: Intermediate 52 (0.8 mg, 0.9 
µmol) was dissolved in dioxane and treated with 0.5 M HCl. The reaction proceeded 4 
hours followed by removal of solvent yielding a fully deprotected HCl Salt (0.5 mg, 84%) 
1H NMR (400 MHz, CD3OD) 1H NMR (400 MHz, CD3OD) δ 7.44 (s, 1H), 7.02 (d, J = 4.0 
Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 6.22 (s, 1H), 4.23 – 4.12 (m, 1H), 3.81-4.02 (m, 2H), 
3.49 (s, 1H), 3.40 – 3.34 (m, 2H), 3.25 – 3.12 (m, 4H), 2.61 (t, J = 7.7 Hz, 2H), 2.52 (s, 
2H), 2.29 (s, 2H), 2.26 – 2.15 (m, 3H), 1.72-1.30 (m, 30H). NMR (CD3OD, 162 MHz δ -
.20 (1P). ESMS: 713.3 [M+H]+ 
Synthesis of (R)-(6-((3-((bis(benzyloxy)phosphoryl)oxy)-2-
heptanamidopropyl)amino)-6b-iosx(4o,h5e-xdyiml)ceathrobxaym-2a-
tenitrobenzyl) phosphate (54) : To an eppendorf tube charged with a stir bar and the 
bis(triethy- lammonium) salt of uncaged model compound 10 (0.7mg, 0.0008 mmol) was 
added MeOH (200 µL) followed by aq. HCl (1 M, 2.4 µL). To the stirring solution was 
added diazonium compound 2 (1.4 mg, 0.0064 mmol). The reaction mixture was stirred 
at room tem- perature for 10 min and evaporated to dryness. 31P NMR of the crude 
material showed incomplete reaction. To the same crude material was added MeOH 
(200 µL) followed by HCl (1 M, 3.0 µL). To the stirring solution was added diazonium 
compound 1 (1.4 mg, 0.0064 mmol). The reaction mixture was stirred for 10 minand the 
solvent was re- moved. 31P NMR of crude mixture showed complete consumption of 
the starting material. The reside was purified by column chromatog- raphy over silica gel 
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(4% MeOH in CH2Cl2) to provide 11 (0.5 mg, 59%) as red solid. 
1H NMR (400 MHz, 
CD3OD): δ 7.63 (s, 2H), 7.34 (s, 1H), 7.04 (s, 2H), 6.94 (d, J = 3.9 Hz, 1H), 6.27 (d, J = 
4.1 Hz, 1H), 6.16 (s, 1H), 5.41 (d, J = 8.1 Hz, 4H), 4.16 (m, 3H), 3.87 (s, 12H), 3.38 (m, 
2H), 3.15 (m, 4H), 2.57 (t, J = 8.1 Hz, 2H), 2.46 (s, 3H), 2.24 (s, 3H), 2.16 (q, J = 7.0, 
14.0 Hz, 4H), 1.55 (m, 6H, 3 CH2), 1.28 (br. s, 8H), 0.86 (td, J = 6.5, 13.5 Hz, 3H). 
31PNMR (161.5 MHz, CD3OD): δ–1.88 (1P). ESMS: m/z 572.5 (M − 
C18H20N2O12P)
+. 
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CHAPTER 4. INVESTIGATION OF CELLULAR PHOSPHOLIPID METABOLISM 
WITH FLUOURESCENT REPORTERS 	
4.1	Introduction	
 
With a suite of fluorescent reporters in hand, shown in Figure 4.1 and described 
in Chapter 2 of this dissertation, as well as a successful delivery method for charged 
PIPs described in Chapter 3, we sought to confirm the capability of these reporters to 
undergo cellular metabolism to a variety of PIP metabolites. We chose to analyze 
cellular activity of DAGK using our BODIPY-DAG-C15 reporter as well as cellular 
activity of PI3K using BODIPY-PIP2-C15 in a variety of breast cancer cell lines due to 
the prevalence of mutations in multiple PIP modifying enzymes including PI3K and 
PTEN [5, 17, 37, 44, 129]. In previous studies using classical methods of detection 
including radiolabeled substrate, PI3K was stimulated under variety of conditions 
including insulin growth factor (IFG), EGF and N-formyl-met-leu-phe (fMLP). In these 
studies, a distinct difference in metabolic profiles, specifically PIP3 prodiction is 
observed with PIP3 capable of being resolved by TLC following short (<10 minutes) 
stimulation whereas limited to no detectable PIP3 is observed in nonstimulated samples 
[130]. Likewise, other lipid modifying enzymes including diacylglycerol kinase (DAGK) 
have also been shown to be important in anchorage independent growth of breast 
cancer cells [22, 61, 109, 131]. Hepatocyte growth factor (HGF) stimulation lead to an 
increase in production of PA via activation of DAGK in MDA-MB-231 cells as well as 
dose dependent DAGK stimulation by synthetic DAG and other lipid metabolites via 
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radiolabeled TLC analysis[109]. We chose to examine the metabolite distribution in 
multiple breast cancer cell lines seen in Figure 4.2A and posses mutations within the 
PI3K pathway highlighted in Figure 4.2B. MDA-MB-436 cells do not express tumor 
suppressor enzyme PTEN, which catalyzes the dephosphorylation of the 5-phosphate 
in PIP3. Alternatively, MDA-MB-453 cells possess the PI3K mutation H1047R, which 
leads to increased basal and stimulated activity of the enzyme through increased affinity 
for lipid binding [46]. These genetic changes should result in higher levels of PIP3 in 
MDA-MB-436 and MDA-MB-453 cells. We also chose to compare these 2 cell lines for 
their overall distribution of metabolites to better understand how the collective of 
metabolites is controlled in the various disease models and the effects of the pathway 
mutations on metabolite distribution. 
 
 
 
	
Figure 4.1 Suite of Fluorescent Reporters to Probe Various PIP 
Metabolic Pathways: A suite of fluorescent reporters with the sn-2 
and sn-3 chains held constant for separation by CE. The synthesis 
for these compounds is described in Chapter 2. 
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In this chapter, we describe the application of our suite of fluorescent-tagged 
PIPs and lipid metabolites for monitoring of cellular PIP metabolism first utilizing 
BODIPY-DAG-C15 to demonstrate the proof of principle. We then used BODIPY-PIP2-
C15 in complex with the CART systems for delivery, described in chapter 3, to monitor 
metabolite distribution following a variety of incubation times. We believe this method 
when coupled with TLC and fluorescent scanning and/or CE-LIF will be capable of 
providing a detailed profile of multiple PIPs simultaneously with the capability of 
monitoring changes due to pathway mutations, stimulation, or inhibition.  
 
4.2 Results and Discussion 
4.2.1 Concentration Dependent Production of PA using BODIPY-DAG-C15 
As a proof of concept, we first examined the conversion of BODIPY-DAG-C15 to 
its corresponding phosphorylated metabolite by DAGK, BODIPY-PA-C15. It has been 
A.	
Cell	Line	 PI3K	Pathway	Mutation	 Phenotypic	Result	
MDA-MB-436	 PTEN	(-/-)	 No	PTEN	Expression	
MDA-MB-453	 PI3K	(H1047R)	 Increased	Basal	and	Stimulated	Activity		
B.	
	
Figure 4.2: Breast Cancer Cell Lines for PI3K Pathway Metabolic 
Analysis: A. Table of selected breast cancer cell lines, associated 
PI3K pathway mutation, and phenotype of the cells. B. Schematic 
showing locations and result of mutations within the PI3K Pathway.  
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demonstrated on various occasions that cellular PA production increases when 
incubated with increasing concentrations of DAG using radiolabeled substrate and TLC 
analysis [11, 21]. We sought to duplicate this result using our fluorescent BODIPY-
DAG-C15 reporter. Previously, we have demonstrated that BODIPY-DAG-C15 is cell 
permeable. HEK293-AD cells were thus incubated with 2, 10, 50, or 100 µM of 
BODIPY-DAG-C15 for 5 minutes which lead to optimal PA production as PA is quickly 
degraded with little remaining radiolabeled PA present after 15 minutes of incubation 
[11, 21]. Folch lipid extraction of slightly acidic chloroform:methanol was performed to 
isolate the fluorescent metabolites and subsequently analyzed by TLC [21, 59]. A 
stronger fluorescent signal consistent with the same Rf of synthesized BODIPY-PA-C15 
standard is observed when incubated with increasing concentrations of DAG as seen in 
Figure 4.3, consistent with previous reports using a di-C8 DAG substrate [11, 21]. 
 
	
Figure 4.3 Concentration Dependent Increase of PA Production 
with BODIPY-DAG-C15: HEK293AD cells were treated with 
increasing concentrations (2-100 µM) of BODIPY-DAG-C15 for 5 
minutes followed by lipid extraction and TLC analysis. A spot 
consistent with PA is produced in increasing intensity in a dose 
dependent manner. 
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This experiment highlighted the utility in using our fluorescent suite of molecules as both 
a reporter, in the case of DAG-C15, and a metabolic product in the form of PA. 
Likewise, it demonstrates that it is feasible to use our technology to monitor 
environmental changes within the cell. 
4.2.2 Delivery of BODIPY-PIP2-C15:CART Complex to Breast Cancer Cells 		
With the ultimate goal of monitoring PIP3 generation in breast cancer cells, we 
wanted to ensure that our previously explored method of delivery utilizing a CART: 
BODIPY-PIP2-C15 complex was also effective for delivery to breast cancer cell lines.  
MDA-MB-436 and 453 cells were incubated with CART:PIP2 complex with a final 
BODIPY-PIP2-C15 concentration of 500 nM. Cellular fluorescence was examined after 
of incubation for 1 and 18 hours, respectively. As seen in Figure 4.4 the CART system 
was capable at efficient and robust delivery of fluorescent reporter, with only 453 cells 
pictured.  
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4.2.3 Cellular Analysis of BODIPY-PIP2 Metabolites in MDA-MBA-436 Cells  
Following confirmation of cellular delivery into breast cancer cell lines, we sought 
to analyze the basal metabolic activity in MDA-MB-436 using both CARTs G7 and A11 
with BODIPY-PIP2-C15. Ideally we would be able to monitor basal metabolism with a 
distribution pattern of fluorescent metabolites that reflects endogenous metabolite 
distribution.  Because these cells lack PTEN expression, we would expect to see a 
buildup of PIP3 over time with the inability to metabolize the product back to PIP2.  Cells 
were treated with CART:PIP2 complex with a final BODIPY-PIP2-C15 concentration of 
500 nM. Following incubation for 3 and 12 hours cell pellets were collected and lipids 
were extracted for analysis. As shown in Figure 4.5, multiple metabolites were 
Figure 4.4. Delivery of BODIPY-PIP2-C15 into MDA-MB-453 cells 
with CARTs: MDA-MB-453 cells (200,000 cells) were plated into a 35 
mm dish and incubated at 37 oC with 5% CO2 for 24 h. The growth 
medium was replaced with serum free DMEM before the cells were 
treated with a 1:1 complex of BODIPY-PIP2-C15 and A11 or G7, or 
BODIPY-PIP2-C15 alone.  The final concentration of BODIPY-PIP2-
C15 was 500 nM. The cells were washed with DMEM twice before 
images were recorded with a confocal microscope. 
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generated using both A11 and G7, with slightly different metabolite profiles. Fluorescent 
standards of BODIPY-DAG-C15, BODIPY-PA-C15 and BODIPY-PtdIns-C15, and 
enzymatically generated BODIPY-PI(4)P-C15 were used to identify metabolites present 
in the samples. Both samples lead to the generation of a high level of PtdIns with 
increasing concentration of PIP over time. TLC analysis cannot assign the identity of the 
PIP as two possible isomers, PI4P and PI5P, should have similar Rf values. We thought 
it is likely to be PI4P, because previous studies analyzing the effect of Wnt stimulation 
on PIP metabolism showed an increase in PIP2 production that was subsequently 
blocked by treating cells with siRNA targeting PI4K, indicating PI(4)P is a key 
intermediate in PIP2  production [9, 10]. These results closely represent endogenous 
PIP distribution with PtdIns being the most abundant fluorescent metabolite followed by 
PIP2 and the intermediate PIP suggesting our system was successful in monitoring 
multiple metabolite generation simultaneously while being distributed throughout the 
PIP metabolic pathway similarly to endogenous metabolites. Interestingly, the 2 CARTs 
also yielded different profiles of metabolites with the cells treated with A11 showing a 
large abundance of fluorescent PA whereas little was generated with the G7 delivery 
system. This could be related to the difference in uptake of the systems that was 
observed in fluorescence microscopy. This distribution of metabolites is remarkably 
similar to distribution of metabolites seen when doing long-term (>24 h) incubation with 
radiolabeled substrate [39, 66, 128]. 
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Despite this positive result, no quantifiable PIP3 was generated in this 
experiment. While we would expect to see increased accumulation of PIP3 due to the 
lack of PTEN, it is possible PIP3 could be terminated through SHIP metabolism 
generating PI(3,4)P2, which would comigrate with PI(4,5)P2 on TLC. Future experiments 
using a SHIP inhibitor should be performed to attempt to ‘trap’ any PIP3 produced over 
time as illustrated in Figure 4.6. 
	
Figure 4.5 Analysis of Fluorescent Metabolite 
Distribution in MDA-MB-436 Cells: Cells (6 million) were 
treated with 500 nM of BODIPY-PIP2-C15:CART as 
complexes as previously described for the indicated time 
points followed by lipid extraction of cell pellets. 
Metabolites were assigned using synthesized standards 
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4.2.4 Cellular Analysis of BODIPY-PIP2-C15 Metabolites in MDA-MB-453 Cells 
With the goal of monitoring PIP metabolism in patient samples that will have 
unique genetic profiles, we wanted to examine and compare the metabolism of our 
reporter in another breast cancer cell line MDA-MB-453. These cells posses a mutation 
in the P110a subunit of PI3K that renders the enzyme constitutively active and should 
result in an increase in PIP3 generation over time. Cells were treated with G7-
CART:PIP2 complex with a final BODIPY-PIP2-C15 concentration of 500 nM. Following 
incubation for 1 and 3 hours cell pellets were collected and lipids were extracted for 
analysis. We chose to do a shorter time course to achieve a higher concentration of 
cellular BODIPY-PIP2-C15 before it undergoes cellular distribution with the goal of 
monitoring production of PIP3. As with the 436 cells, no cellular PIP3 was observed with 
a similar distribution of PtdIns and PIP as seen in Figure 4.7. However, unlike the 436 
cells the most abundant fluorescent signal comes from PIP2 and not PtdIns suggesting 
differential metabolism of the reporter despite using the same delivery vehicle.  The high 
concentration of PIP2 could also be a result of the presence of active PTEN in MDA-MB-
	
Figure 4.6 Method to ‘Capture’ Fluorescent PIP3 Produced 
in MDA-MB-436 Cells: Treating PTEN deficient cells with a 
SHIP inhibitor over a long-time course incubation may allow for 
trapping of any PIP3 produced that is below the detectable limit 
in previous experiments. 
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453 cells that could diminish PIP3 back to PI(4,5)P2 despite the overactive PI3K.  This 
presence of PTEN could explain the difference in metabolite profiles between MDA-MB-
436 and 453 cells suggesting differential mechanisms to diminish total PIP3 produced.  
 
4.3 Conclusions and Future Directions 
 We have successfully demonstrated the capability of using a fluorescent reporter 
for analysis of various lipid metabolites. BODIPY-DAG-C15, which freely enters cells, 
was converted to the corresponding PA in a dose dependent fashion showing that 
indeed a fluorescent reporter is capable of monitoring changes in lipid metabolism. 
Further experiments need to be performed using a single low concentration of BODIPY-
DAG-C15 and various stimulation events. One such experiment that could verify the 
system against literate precedent would be the analysis of PA production using 
BODIPY-DAG-C15 and stimulating with the non-fluorescent di-C8-DAG, as this 
	
Figure 4.7 Analysis of Fluorescent Metabolite Distribution in 
MDA-MB-453 Cells: Cells (6 million) were treated with 500 nM 
of BODIPY-PIP2-C15:CART complexes as previously described 
for the indicated time points followed by lipid extraction. 
Metabolites were assigned using synthesized standards. 
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substrate has been used to stimulate DAGK activity as previously described in this 
chapter.  This will be more representative of a biological application where a small 
amount of fluorescent reporter would be used to monitor intracellular metabolism.  
DAGK has been widely studied in Jurkat cell lines, therefore we plan to apply this 
technology to analysis of PA production and metabolite distribution in a leukemia model 
system[6, 11, 21, 22, 59, 132].   
 We have also demonstrated the strategy for PIPs generating multiple metabolites 
using BODIPY-PIP2-C15. In combination with CARTs A11 and G7, we were successful 
in delivering BODIPY-PIP2-C15 to multiple breast cancer cell lines harboring separate 
and distinct PI3K pathway mutations.  Upon delivery, BODIPY-PIP2-C15 underwent 
cellular metabolism to generate a variety of PIP metabolites that were confirmed using 
synthesized standards. An incubation time of 3 and 12 hours with BODIPY-PIP2-C15 in 
MDA-MB-436 cells revealed a distribution of metabolites consistent with the 
endogenous ratios of PIPs [20, 39, 65, 66, 68]. Further, this profile was consistent with 
previously reported basal PIP analysis using radiolabeled inositol and ATP over a 
similar time course[66, 133]. Unfortunately we were unable to obtain measurable 
generation of PIP3 by TLC. Because PIP3 is a potent secondary activator, it is quickly 
generated and degraded by multiple mechanisms; therefore it is likely any PIP3 is below 
our measurable range[16, 17, 25]. Comparison of PIP3 production  using mass 
spectrometry following fMLP stimulation in MCF10A cells showed that in many cases 
less than 1% of a total PIP2 population is converted to PIP3[64, 67] . Likewise, there has 
been more success in measuring PIP3 production using radiolabeled substrates under 
stimulatory conditions such as EGF with maximal PIP3 production at 5 minutes following 
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stimulation in HL60 cells. Therefore it is probable that any PIP3 produced in 
unstimulated cells is below the level of detection. Future experiments will be performed 
using cell lines such as MCF10A or HL60 under a variety of stimulatory conditions, 
including fMLP and EGF, which have previously been demonstrated to produce 
detectable levels of PIP3 in bulk cell analysis by TLC and mass spectrometry as well as 
single-cell analysis by flow cytometry [7, 67, 133]. Such an experiment is important to 
verify we are capable of measuring changes to cellular metabolism following stimulation 
events using BODIPY-PIP2-C15. Likewise, treatment of MDA-MB-436 cells with a SHIP 
inhibitor to ‘trap’ any PIP3 produced would also be a useful experiment in examining the 
utility of our system following cellular perturbation using pharmacological agents.  
 In a shorter incubation of BODIPY-PIP2-C15 using carrier G7 in MDA-MB-453 
cells harboring the activating H1047R PI3K mutation we saw the major metabolite 
present to be the delivered reporter with fluorescent PtdIns present as well. As before 
we were unable to detect fluorescent PIP3 in the mixture, which could be a result of 
numerous previously described mechanisms. However, because the system in this time 
shows a less complex metabolic profile these conditions can be utilized to monitor 
future studies performed following receptor stimulation. This will give the greatest 
opportunity to both analyze production of PIP3 while also allowing comparison of the 
distribution of various metabolites following receptor stimulation. Because of the shorter 
incubation time required with CART G7 it will be used exclusively in future experiments. 
Studies in previously mentioned cell lines will be performed following a variety of 
incubation times prior to stimulation to better understand the optimal range for 
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monitoring PIP3 production. It is also possible various metabolic pathways will require 
unique incubation times and metabolite distribution for effective study.  
 Another future direction for this work is the modification of the reporter to serve 
as a more efficient substrate toward PIP modifying enzymes. While we have 
demonstrated here and in chapter 2 that a PIP2 reporter with a C15 alkyl chain is 
efficiently metabolized to a variety of metabolites it still posses less hydrophobicity than 
endogenous PIP2 which contains stearic and arachidonic acid on the DAG moiety. This 
could explain the lack of PIP3 production as BODIPY-PIP2-C15 is competing against 
endogenous substrate to be metabolized. One such modification would be the addition 
of more hydrophobic side chain at the sn-2 position and comparing the efficacy of the 
reporters in a cellular based assay. This could also be beneficial in achieving PM 
localization as a majority of the delivered BODIPY-PIP2-C15 appears in the cytosol.  
 Another structural change to the reporter would be the removal of the fluorophore 
for the addition of a terminal alkyne that could be tagged with a fluorophore using ‘click-
chemistry.’ Such an approach has been shown effective on tri-functional DAG and PA 
reporters for visualization[98, 134]. We have synthesized an alkyne containing PtdIns 
(AK-PtdIns-C15; Figure 4.9A) by replacing the fluorophore with a terminal alkyne at 
the sn-1 position using an NHS ester as previously described. We have confirmed 
generation of fluorescent product via ‘click chemistry’ as shown in Figure 4.9B. Getting 
rid of the bulky and exogenous fluorophore will further allow for reporters to better mimic 
endogenous substrate. Likewise, modifications can be made to both alkyl chains on 
DAG to contain a terminal alkyne at either position. Such a method could increase the 
ability of our reporters to be metabolized in the cell. Future experiments comparing 
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alkyne containing reporters and fluorescent reporters may give further valuable insight 
into the structural requirement for effective metabolic measurement.  
 
Another potential direction for this platform is the use of dual fluorophores with unique 
excitation and emission wavelengths that could be used to tag multiple substrates. For 
instance PIP2 tagged with BODIPY which is excited and detected using a 488 nm blue 
A.	
	
B.	
	
Figure 4.8 Structure of AK-PtdIns-C15 and Fluorophore 
Addition via ‘Click-Chemistry’: A. Structure of AK-PtdIns-C15 
which when reacted with Fl-Azide under ‘click’ chemistry 
conditions generates a fluorescent product. B.  TLC analysis of 
‘click-chemistry’ reaction, a new fluorescent spot was generated 
only in the sample containing both AK-PtdIns-C15 and catalytic 
CuSO4 indicating successful generation of the fluorescent 
metabolite.  Reaction was performed in water with 2 mM CuSO4, 2 
mM sodium ascorbate, and 2 mM THPTA for 30 minutes. 	
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laser line and PtdIns tagged with TAMRA which is excited using a 523 nm green laser 
line,  could be delivered to cells and then the specific pools of metabolites could be 
monitored using CE-LIF and analyzing separately for BODIPY and TAMRA metabolites 
through excitation with their unique laser lines [62, 76, 77] .  
 Overall, this work has demonstrated the feasibility of using PIP reporters for 
analysis of cellular metabolic activity. Numerous chemical biology approaches can 
further be applied to this technique to increase the scope of biological processes that 
can be examined, with long-term aspirations of diagnostic application. 
4.4 Experimental  
All reagents were obtained from commercial sources and were used without further 
purification. 
4.4.1 Cell Culture 
HEK293AD and MDA-MB-453 cells were cultured in DMEM with 10% FBS and 1% 
antibiotic-antimycotic. MDA-MB-436 cells were cultured in DMEM with 10% FBS, 10 
mg/mL insulin, 16 mg/mL glutathione, and 1% antibiotic-antimycotic. All cells were 
grown at 37 oC with 5% CO2, and split when the confluency reached approximately 
90%. 
4.4.2 Delivery of BODIPY-PIP2-C15 to Breast Cancer Cells 
Cells as indicated (200,000 cells) were plated into a 35 mm dish in growth medium and 
cultured at 37 oC with 5% CO2 for 24 h. The medium was replaced with serum free 
DMEM before the BODIPY-PIP2-C15/CART complex was added. To form the complex, 
BODIPY-PIP2-C15 (1.6 mL, 1.0 mM stock in H2O) was added to acidified PBS (pH 5.5, 
47.5 mL). The CART (A11 or G7, 0.6 mL) was subsequently added and the components 
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were gently mixed through pipetting. After 1 min, the complex was added to the medium 
and incubated with the cells for indicated time before analysis was carried out. 
4.4.3 Extraction of Lipids from Cell Pellet 
150 µL of 40:20:1 (v:v:v) Chloroform:Methanol:HCl was added to the cell pellet and left 
at room temperature for 10 minutes. 50 µL of CHCl3 and 50 µL of water were added and 
the mixture vortexed heavily for 3 minutes. The mixture was then centrifuged at 4 oC at 
3200 RPM for 8 minutes resulting in phase separation. The bottom layer was collected, 
dried under a stream of N2 and resuspended in 30 µL of 1:1 CHCl3:MeOH (v:v) for TLC 
analysis.  
4.4.4 TLC Analysis of Lipid Metabolites 
TLC plates (Merck, Silica Gel-60) were pre-treated with a solution of 1.2% potassium 
oxalate and 1.2 mM EGTA in MeOH/water (v:v = 2:3) and heated at 110 °C for 20 
minutes before use. Reaction mixture was diluted in CHCl3/ MeOH (v:v = 1:1) and 
spotted on a TLC plate directly. The TLC plate was then developed in 
CHCl3:Acetone:MeOH:AcOH:water (v:v:v:v:v = 80:30:26:24:14) or 
CHCl3:Hexane:Metahnol:Acetic Acid (v:v:v:v= 50:30:10:5) and scanned on a Typhoon 
9400 Variable Mode Imager (lex/lem = 488 nm/520 nm). The fluorescence intensity of 
various spots on the TLC plate was quantified with ImageQuant software (V.5.0) 
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 Appendix 
Appendix A CMC Determination of Fluorescent PIP2 Analogs 
 
 
 
Appendix B Kinetic Analysis of Fluorescent PIP2 Analogs 
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Appendix C 1H NMR Spectra (CDCl3)  of compound 5D is an example of fully 
protected intermediate in PIP2 synthesis 
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Appendix D 13C NMR Spectra (CDCl3) of compound 5D is an example of fully 
protected intermediate in PIP2 synthesis 
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Appendix E 31P NMR Spectra (CDCl3) of compound 5D is an example of fully 
protected intermediate in PIP2 synthesis 
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Appendix F  1H NMR (CD3OD) of PIP2-C15 is an example of a final fluorescent PIP2 
Analog 
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Appendix G 31P NMR (CD3OD) of PIP2-C15 is an example of a final fluorescent PIP2 
Analog 
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Appendix H HRMS analysis of PIP2-C15 is an example of a final PIP2 analog 
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Appendix I 1H NMR (CD3OD) of BODIPY-PtdIns-C15  
 
Appendix J 31P NMR  Spectra (CD3OD) of BODIPY-PtdIns-C15  
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Chemical Formula: C45H73BF2N3O14P 
Exact Mass: 959.49 
[M+H] Predicted: 960.49 
M+H Calculated: 960. 96 
 
Appendix K HRMS of BODIPY-PtdIns-C15 
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Appendix J 1H NMR Spectra (CDCl3) of BODIPY-DAG-C15 
 
Appendix J 13C NMR spectra of BODIPY-DAG-C15 
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Appendix K 1H NMR Spectra (CD3OD) of Compound 36 
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Appendix L 31P NMR Spectra (CD3OD) of compound 36 
 
Appendix M 13C NMR spectra (CD3OD) of Compound 36 
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Appendix N 1H NMR Spectra (CD3OD) of compound 53 
 
Appendix O 31P NMR spectra (CD3OD) of compound 53 
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Appendix P 1H NMR spectra (CDCl3) of BODIPY-PA-C15 
 
Appendix Q 31P NMR Spectra (CDCl3) of BODIPY-PA-C15 
-2-101234567891011121314
f1	(ppm)
-500
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500007_067_PA_Clmn_speedvac_PROTON_001
4.
05
28
.0
2
2.
02
17
.8
1
7.
16
2.
75
2.
29
3.
33
1.0
8
0.
94
1.5
5
0.
07
0.
84
0.
85
0.
87
0.
88
0.
89
1.0
9
1.2
3
1.2
4
1.2
5
1.2
9
1.3
6
1.3
8
1.4
0
1.4
2
1.5
2	
HD
O
1.5
4	
HD
O
1.5
6	
HD
O
2.
01
2.
17
2.
22
2.
24
2.
25
2.
27
2.
29
2.
54
2.
59
2.
61
2.
63
2.
64
3.
13
3.
15
3.
17
3.
18
3.
22
3.
24
3.
26
3.
34
3.
35
3.
76
3.
82
4.
11
4.
33
4.
36
5.
11
5.
13
6.
11
6.
16
6.
27
6.
28
6.
86
6.
87
7.
09
7.
12
7.
19
7.
26
	c
dc
l3
7.
47
-40-30-20-100102030405060708090100110120130140150160170180190
f1	(ppm)
-60
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140007_067_PA_Clmn_speedvac_PHOSPHORUS_001
2.
12
	125	
 
Appendix R 1H NMR spectra (CD3OD) of BODIPY-PIP2-C15 
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Appendix S 31P NMR spectra (CD3OD) of BODIPY-PIP2-C15 
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